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ABSTRACT 
Extracellular  matrix  (ECM)  constitutes  a  large  component  of  our  tissue  structure. 
Primarily, ECM provides structural and adhesive support to our cells, but it also controls cellular 
signaling  and  behavior.  Homeostasis  of  extracellular  matrix  composition  and  function  is 
maintained by our body through a balanced synthesis, degradation and remodeling of ECM. 
However, under pathological conditions and genetic mutations, ECM homeostasis is disrupted 
due to deregulation in ECM synthesis, assembly, remodeling, and degradation. A number of 
diseases, including cardiovascular diseases and cancer, are found to occur due to alterations in 
ECM. Therefore, targeting ECM can be an attractive therapeutic approach to treat these diseases, 
and it requires our complete understanding of the ECM molecules and the molecular mechanism 
it  employs  in  controlling  cellular  functions.  To  this  end,  this  study  is  aimed  at  the 
characterization of two ECM proteins—Matrix Gla Protein (MGP) and Lumican—for their roles 
in vascular development, angiogenesis, and cancer. Findings from this study show that MGP is a 
critical ECM regulator that promotes angiogenic resolution by suppressing endothelial sprouting 
and  stabilizing  vascular  lumen  formation.    In  addition,  MGP  also  inhibits  tumor  growth  by 
inhibiting tumor angiogenesis. On the other hand, our findings show Lumican suppresses tumor 
growth and has anti-angiogenic activity in a context specific manner.    iv 
 
 
 
PREFACE 
This study provides a review on ECM proteins and their importance in human health and 
diseases. The main focus of this study, however, is to highlight Matrix Gla Protein (MGP) and 
Lumican  as  critical  ECM  regulators  of  angiogenesis  and  cancer.  Our  findings  on  MGP  are 
published in Microvascular Research Journal and we plan to submit our findings on Lumican to 
a peer-reviewed journal soon in the future.  
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CHAPTER I 
EXTRACELLULAR MATRIX (ECM): IMPLICATIONS FOR HUMAN HEALTH 
AND DISEASES 
 
Extracellular Matrix: Structural and Functional Overview 
Our tissues are not made up of only cells but also contain a significant volume of 
extracellular spaces. These extracellular spaces are packed with a heterogeneous fusion of 
macromolecules  including  proteins,  glycoproteins,  proteoglycans,  and  polysaccharides 
deposited  by  cells,  which  are  collectively  called  the  extracellular  matrix  (ECM)  [1]. 
Although the identity of ECM constituents is far from complete, a subset of those that 
have been identified and characterized is listed in Table 1.  
Primarily,  there  are  two  distinct  types  of  ECM—the  basement  membrane  and 
interstitial matrix. The basement membrane is a specialized ECM distinct from that of 
interstitial matrix.  The basement membrane is produced by epithelial cells, endothelial 
cells,  and  stromal  cells  and  separates  epithelium  or  endothelium  from  its  underlying 
stroma.  It  is  more  compact  and  less  porous  than  interstitial  matrix  and  is  mainly 
composed of type IV collagen, laminin, fibronectin, perlecan, and linker proteins such as 
nidogen and entactin [2]. On the other hand, interstitial matrix is markedly different from 
the basement membrane in its composition and function. Interstitial matrix is comprised        
 
 
2 
of fibrillar collagens, proteoglycans, and glycoproteins, which are highly charged and 
hydrated, and thus provides great tensile strength to tissues.   
ECM  has  distinct  physical,  biochemical,  and  biomechanical  properties,  which 
collectively impacts cell behavior [1]. For instance, physical properties of ECM include 
its rigidity, insolubility, porosity, and spatial arrangement that confer upon its role as 
scaffold to support tissue structure. Cell surface proteins such as integrins bind to various 
ECM molecules including collagens, glycoproteins, and proteoglycans and help cellular 
adhesion.  Furthermore,  cell-matrix  interaction  also  creates  a  mechanical  signal  that 
changes intracellular cytoskeletal rearrangements and control cell motility. In addition, 
cell-matrix interactions define cell shape and polarity. More importantly, ECM provides 
cell signaling and regulates various cellular parameters including proliferation, survival 
and growth, apoptosis, and differentiation during development as well as in adult life of 
living organisms. A subset of ECM molecules, besides their structural roles, also has cell 
signaling and regulatory functions, and these molecules are categorized as “matricellular” 
molecules [3]. 
Collectively, ECM provides both physical support and biochemical signals to our 
body  cells,  which  are  requisites  for  cellular  organization  into  multicellular  form. 
Therefore,  ECM  is  highly  conserved  evolutionarily  across  species.  For  instance,  a 
number of ECM molecules such as fibrillar collagen, the basement membrane (collagen 
IV,  laminin,  Fibronectin,  Perlecan),  Fibrillin,  Thrombospondin,  Agrin,  Syndecan,  and 
Glypican  are  found  in  simple  organisms  such  as  choanoflagellates,  sponges,  and  c. 
elegans. During the evolutionary process, higher organisms such as vertebrates innovated 
other components of ECM (Integrin, CCN, vitronectin, Tenascin, etc) along with cell-       
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matrix  and  matrix-matrix  interacting  domains  [4-7].  Therefore,  ECM  components  are 
vital elements that are believed to unite the whole animal kingdom into a monophyletic 
group  of  multicellular  organisms  [8].  The  importance  of  cell-matrix  interaction  is 
illustrated in Figure 1.  
ECM in Human Health and Diseases 
Appropriate  ECM  composition  and  function  is  requisite  during  embryonic 
development and in the maintenance of tissue homeostasis during adult life [9]. ECM 
interacts  with  cells  and  controls  cellular  adhesion,  migration,  differentiation,  and 
morphogenesis, which are critical events during embryonic development. ECM interacts 
with cells through a number of cell surface receptors such as integrins. To fulfill their 
biological need for appropriate adhesion, signaling cues, and migratory passage, cells can 
manipulate the (or their) ECM through a regulated cycle of synthesis, degradation, and, 
remodeling  to  create  an  appropriate  extracellular  microenvironment  [1].  For  instance, 
degradation  of  the  basement  membrane  and  stromal  ECM  by  endothelial  cells  is  a 
common process during physiological angiogenesis that occurs during wound healing and 
tissue  repair.  Additionally,  during  developmental  processes,  ECM  remodeling  and 
makeover  are  critical  events  in  guiding  proper  cellular  proliferation,  migration, 
differentiation, and tissue morphogenesis [9]. In addition, infiltration and migration of 
immune  cells  during  inflammatory  response  is  another  common  example  where  the 
remodeling of both the basement membrane and interstitial ECM takes place for a proper 
recruitment of immune cells to the infected tissue [10]. Similarly, cell-matrix interactions, 
matrix remodeling, and matrix degradation is commonly found in the pathophysiology of 
number of diseases. Most importantly, ECM deregulation is commonly found in cancer        
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during its growth, invasion, metastasis, and angiogenesis [11]. Collectively, the changes 
in ECM create a favorable “microenvironment” within the tissue to foster appropriate 
cellular function both in physiological as well as in pathological conditions. Deregulation 
of ECM under pathological conditions and its consequences are illustrated in Figure 2.  
Changes in ECM is a common mechanism both in physiological as well as in 
pathological conditions. The changes during physiological processes are temporary which 
can be reversed to its homeostasis. However, under pathological conditions, changes in 
ECM  occur  permanently  and  are  beyond  the  control  of  our  bodily  regulations.  For 
instance,  under  pathological  conditions  such  as  cancer  invasion,  the  activity  of 
collagenase  and  other  ECM-degrading  proteases  such  as  matrix  metalloproteases  are 
persistently higher. Likewise, the deregulation of endothelial membrane tethered MMP 
(MT-MMPs) dramatically changes angiogenesis responses. Such deregulations in ECM 
function  are  commonly  found  among  a  number  of  human  diseases  including 
cardiovascular abnormalities and cancer.  Therefore, in this chapter, I aim to highlight the 
importance of ECM in vascular function particularly focusing on the pathophysiology 
vascular diseases and cancer.  
ECM and Vascular Diseases 
ECM  surrounds  vascular  tissues,  and  its  proper  functioning  is  critical  during 
vascular development and stabilization of the vascular wall [12-15]. Various cell types 
present  within  vascular  microenvironment  including  endothelial  cells,  mural  cells 
(vascular smooth muscle cells and pericytes), and stromal cells such as fibroblast deposit 
ECM  in  the  vascular  tissues.    The  basement  membrane  is  in  direct  contact  with 
endothelial cells and controls endothelial cell behavior such as angiogenic responses. The        
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interstitial components of ECM interacts with mural cells and together build a stable and 
mature  vascular  wall  [16-18].  Therefore,  alterations  in  ECM  function  changes  the 
structure of vascular tissue and ultimately its function. Therefore, a number of vascular 
diseases are associated with ECM dysfunctions [19-21]. For example, deregulation of 
collagen  due  to  altered  fibroblast  function  results  in  fibrosis  of  cardiac  and  vascular 
tissues.  Compared  to  normal  fibroblasts,  differentiated  myofibroblasts  deposits 
significantly increased the level of collagens, which increases the stiffness of cardiac and 
vascular tissues and thus promote hypertensive conditions. Additionally, these changes in 
the  ECM  of  the  heart  greatly  impacts  systolic  and  diastolic  function,  which  is  also 
associated with hypertensive conditions [20]. 
In  addition,  alterations  in  ECM  due  to  the  dysfunction  of  ECM  degrading 
enzymes  such  as  matrix  metalloproteases  (MMPs)  are  associated  with  cardiovascular 
abnormalities.  For  example,  during  post-myocardial  infarction,  the  increased  MMP 
activity prevents appropriate ECM replacement needed to recover the damaged tissue and 
worsens the condition, which can lead to heart failure [22, 23]. Conversely, decreased 
MMP activity resulting in an excessive accumulation of ECM is also associated with 
several cardiovascular defects including myocardial stiffness, cardiac hypertrophy, and 
hypertension. Besides structural damages, alterations in ECM also change cell-matrix 
interactions, which ultimately change gene expression and cellular function. Therefore, a 
balanced ECM composition is critical in maintaining tissue homeostasis. 
ECM  within  the  vascular  tissues  plays  a  central  role  in  the  pathogenesis  of 
atherosclerosis  [24,  25].  During  the  development  of  atherosclerotic  lesions,  vascular 
remodeling through degradation and reorganization of matrix scaffold of the vascular        
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wall  is  a  primary  step.  For  instance,  in  the  inflammation-induced  atherosclerosis, 
degradation of ECM promotes cell migration, proliferation, and tissue remodeling within 
the vascular wall that allows the development of vascular lesions and plaque build up [26, 
27]. Matrix metalloproteases and their tissue inhibitors are critical players in this process 
since they control matrix degradation and remodeling. Therefore, deregulation of matrix 
metalloproteases  and  their  tissue  inhibitors  (TIMPs)  are  commonly  found  in 
atherosclerosis [28]. In addition, Matrix Gla Protein (MGP), a component of ECM is 
known to have a direct role in the development of atherosclerosis and arteriosclerosis [29, 
30].  MGP is a small ECM protein, which has a primary role as a calcification inhibitor. 
Furthermore,  MGP  also  suppresses  atherosclerosis  since  MGP  deficiency  in  mice 
promoted atherosclerosis and its overexpression in the atherosclerotic lesion significantly 
reduced  atherosclerotic  plaque  buildup  [31].  In  addition  to  these  cardiovascular 
abnormalities, ECM also regulates angiogenesis, and consequently, the deregulation of 
ECM is associated with abnormal angiogenesis commonly found in a number of human 
diseases including cancer. 
ECM and Cancer: An Overview 
Cancer  development  involves  distinct  phases  including  initiation,  growth  and 
survival, angiogenesis, invasion, and metastasis. Initiation of cancer begins by cellular 
transformation following defects in the cellular program that regulates cell growth and 
death. In cancer, cells become self-sufficient in pro-growth and survival signals by either 
1) gain-of-function mutation in pro-oncogenic genes or 2) loss-of-function mutation in 
tumor suppressor genes, or 3) both. Once a cell becomes cancerous, it grows as a primary 
tumor within the local tissue. Eventually, however, primary tumors invade tissues, get        
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access to the lymph nodes and blood stream, and deposit in distant tissues where they 
establishes as secondary tumors called metastases. Tumors that remain in local tissues are 
“benign tumors” and those metastasize to distant tissues are “malignant tumors” [32].  
Angiogenesis, invasion, and metastasis are some of the properties of cancer that 
make it a deadly disease. Primary tumor require blood vessel to supply it with essential 
nutrients  and  oxygen  to  grow  beyond  certain  size  (2  mm)  and  eventually  become 
malignant. Therefore, growing primary tumors drive angiogenesis and orchestrate other 
cellular  and  molecular  programs  to  create  a  pro-tumorigenic  niche  called  the  “tumor 
microenvironment”  that  fosters  the  tumors’  growth,  invasion,  and  metastasis.  In 
summary, cancer cells are able to acquire unique capabilities such as ability to overcome 
anti-growth and apoptotic signals to survive and grow, build their own blood vessels by 
angiogenesis, invade surrounding tissues, and metastasize at distant organs [32]. These 
unique capabilities acquired by cancer are collectively called “hallmarks of cancer.”  
ECM and Cancer: Cancer Development and Progression 
Appropriate ECM interaction is a requisite in the maintenance of cancer stem cell 
niche and its fate [11, 33, 34]. Localization of cancer stem cells is critical to maintain 
contact with surrounding niche cells and obtain paracrine signaling to maintain their stem 
cell properties. In addition, stem cell interaction with ECM is also critical to maintain 
their cell polarity and orient mitotic spindle. Such orientation is important to undergo 
asymmetric cell division, an inherent property of stem cells. Therefore, availability of 
appropriate ECM for anchorage is a basic need for the maintenance of cancer stem cells.  
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ECM  is  a  common  regulator  of  cancer  development  and  progression  and 
deregulated ECM dynamics is one of the hallmarks of cancer [11, 35-37]. Cancer cells 
employ a number of cellular and molecular interactions to change the ECM dynamics and 
create a tumorigenic niche.  For example, increased collagen deposition by cancer cells 
and cancer-associated fibroblast enhances integrin signaling and promotes cell survival 
and proliferation [38, 39], which is a requisite for transforming cancer cells.  Increased 
expression of lysyl oxidase (LOX), a collagen cross-linker, is commonly found in cancers 
[40] where its increased expression enhances cross-linking and creates stiff ECM. Stiff 
ECM provides an appropriate condition for focal adhesion assembly and consequently 
the upregulation of cell survival PI3K/MAPK pathway [41]. In addition, a number of 
ECM  proteins  and  their  fragments  have  pro-or-anti  apoptotic  effects  and  tumors  are 
found to selectively manipulate these molecules to evade apoptosis [42, 43]. These and a 
number of other interactions between cancer cell, ECM, and stromal cell selectively de-
regulate ECM to create pro-survival and pro-growth environment necessary for cancer 
initiation and development.  
Furthermore,  cancer  cells  also  interact  with  its  stromal  microenvironment  to 
selectively alter ECM to promote angiogenesis and its invasion and metastasis [44]. For 
instance,  cancer  cells  and  stromal  cells  (cancer  associated  fibroblast,  immune  cells, 
endothelial  cells,  etc.)  produce  a  high  level  of  ECM  degrading  proteases  such  as 
collagenases  and  MMPs  [45].  These  enzymes  collectively  degrade  the  basement 
membrane and promote cancer invasion. In contrast, the linearization and thickening of 
collagen  is  also  commonly  found  in  invasive  cancers.  Such  linearization  of  stromal 
collagen fibers enhances cancer cell adhesion and migration during invasion [41, 46].        
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Therefore, cancers employ both degradation and re-organization of ECM components on 
a need basis to promote their progression. Tumors also remodel vascular the basement 
membrane and perivascular ECM to enhance angiogenesis and metastasis. For instance, 
tumors  and  stromal  cells  produce  MMPs  and  collagenases  to  degrade  vascular  the 
basement membrane to drive tumor angiogenesis [47]. In addition, invasive cancer cells 
also  create  a  more  porous  and  leaky  endothelial  the  basement  membrane  [48]  that 
promotes metastasis and infiltration of immune cells [49]. Recruitment of immune cells 
such as tumor-associated macrophages can produce angiogenic growth factors and ECM 
degrading proteases, which collectively enhances cancer development and progression.  
 In addition, tumors also secrete factors that influence endothelial cell behavior. 
Tumors  increase  integrin  expression  and  enhance  endothelial  cell-matrix  interactions. 
Cell-matrix  interaction  via  integrins  promote  endothelial  survival,  proliferation, 
morphogenesis  [50],  and  migration  required  for  angiogenesis.  Tumors  also  enhance 
angiogenesis  by  suppressing  the  release  of  angiostatic  fragments  from  various  ECM 
molecules such as endorepellin (from perlecan), endostatin (from collagen XVIII), restin 
(from Collagen XV), arresten, canstatin, and tumstatin (from Collagen IV) and create 
pro-angiogenic tumor microenvironment [51]. Moreover, tumors also produce angiogenic 
growth factors such as VEGF and FGF and manipulate ECM to localize these factors and 
create  the  appropriate  angiogenic  gradient.  For  instance,  VEGF  contains  a  heparin-
binding  domain  that  interacts  with  heparin-sulfate  proteoglycans  (HSPGs)  [52-54]. 
Interestingly, tumors are shown to upregulate the expression of these HSPGs (such as 
perlecan) and localize VEGF gradient to promote angiogenesis.  In addition, a number of 
proteoglycans (such as decorin and Versican) also bind to integrins and other cell surface        
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receptors present in the cancer and endothelial cells and modulate tumor cell growth, 
migration, angiogenesis, and metastasis [55-57]. 
Collectively,  ECM  dynamics  is  critical  aspects  of  tumor  development  and 
progression, and tumors employ a complex system of cellular and molecular interactions 
within  the  growing  tumor  microenvironment  to  selectively  manipulate  its  ECM  to 
promote cancer hallmarks such as invasion, angiogenesis, and metastasis.       
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Figure 1. Appropriate cell-matrix interactions are critical in multicellular organisms. 
Cells  tightly  regulate  their  extracellular  matrix  and  deposit  appropriate  matrix 
component into their extracellular space to fulfill their physiological needs. The blue text 
box shows list of common ECM molecules. Besides the synthesis of ECM, cells also 
degrade ECM in a need basis and produces ECM-degrading proteases (displayed in the 
last column of the blue text box). Thus, cells deposit and remodel the ECM and in return 
the ECM provides essential support and signaling system to control cellular behavior. 
Cellular behavior commonly regulated by ECM is shown in a green box in the bottom. 
Thus, cells and their extracellular matrix maintain two-way communication (cells deposit 
ECM and ECM control cell function) to maintain multicellular function. The importance 
of extracellular matrix in multicellular organisms can be highlighted by the evolution of 
ECM in as simple organism as sponges as depicted in the evolutionary map on the right.           
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Figure 2. Deregulation of ECM is detrimental to our health. 
Normally  body  cells  deposit  ECM  that  is  requisite  for  their  physiological 
functioning and it tightly controls its extracellular matrix. However, under circumstances 
such as mutation in the ECM encoding gene and other pathological conditions, alterations 
in the ECM synthesis, assembly, and remodeling is commonly found and that changes the 
normal  ECM  composition  to  abnormal.  Abnormal  ECM  sends  abnormal  signals  and 
manipulates cellular function. Such changes in cellular function due to abnormal ECM 
activity are commonly found in a number of diseases (some of them listed in the green 
box). 
Table 1. Commonly known ECM proteins. 
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CHAPTER II 
ANGIOGENESIS AND ITS REGULATORS: IDENTIFICATION OF NOVEL ECM-
BASED REGULATORS OF ANGIOGENESIS 
 
Introduction 
In the previous chapter, I have highlighted the importance of ECM function in 
maintaining our health and emphasized how ECM components are critical factors in the 
pathogenesis  of  cardiovascular  and  cancer  diseases.  In  the  same  chapter,  it  was  also 
briefly  discussed  that  ECM  impacts  angiogenesis,  which  is  a  requisite  for  cancer 
malignancy. Besides cancer, abnormal angiogenesis is also a common pathogenic factor 
in as many as seventy other human diseases [58-60]. Therefore, therapeutic manipulation 
of angiogenesis represents an effective approach for the treatment of those diseases that 
involves  abnormal  angiogenesis.  Attempts  have  already  been  made  to  treat  cancer 
diseases using anti-angiogenesis therapy, but the results are not satisfactory.  
For  instance,  Avastin,  a  humanized  monoclonal  antibody  against  VEGF 
developed by Genentech, Inc. and approved by FDA for clinical use as anti-angiogenic 
drug, only showed an average increase in lifespan by only 4-6 months with very high cost 
at $ 100,0000/year for colorectal cancer treatment [61]. Also, the response for Avastin is 
variable among different cancers such as colorectal cancer, lung cancer, kidney, brain, 
and breast cancer. In addition, tumors are found to resist anti-VEGF therapies and restore      
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their growth and progression over a period of time [62]. Anti-VEGF treatment is also 
shown  to  impose  serious  side  effects  including  hypertension,  thrombosis,  impaired 
wound  healing,  gastrointestinal  perforations,  fatal  hemorrhages,  fatigue,  anorexia, 
diarrhea, mucositis, handfoot syndromes, and in some cases congestive heart failure [63]. 
Recently  FDA  disapproved  the  use  of  Avastin  in  breast  cancer  treatment  due  to  no 
significant improvement in patient health and survival and due to very serious safety 
concerns (www.FDA.gov).
1 One of the rationales for the failure of anti-VEGF therapies 
is lack of efficacy biomarkers to validate optimal dose and resulting responses in patients 
with different cancer types [63]. Identification of such biomarkers and mechanism of 
action  by  anti-VEGF  treatment  under  different  criteria  would  allow  us  to  determine 
appropriate treatment regiments unique to colorectal, lung, breast cancer, and others. 
 To  this  end,  perhaps  the  variations  in  ECM  components  of  cancer 
microenvironment plays a critical role in modulating anti-VEGF response to cancers, 
since ECMs have been shown to manipulate VEGF signaling during angiogenesis [64-
67]. In addition, changes in the ECM dynamics are critical aspect in the orchestration 
specific cellular and molecular events required for angiogenesis [65, 68, 69]. However, 
the importance of ECM on angiogenesis regulation is overlooked in the design of current 
regiments of anti-angiogenic therapies. Therefore, identification and characterization of 
ECM regulators of angiogenesis is critical not only because it can be a novel therapeutic 
target but also to improve current therapeutics. In this context, the identity of ECM-based 
angiogenic  molecules  represents  an  important,  yet  poorly  understood  avenue  towards 
potential angiogenic-based therapeutics for diseases that involves abnormal angiogenesis 
                                                 
1 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280536.htm      
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such as cancer. Therefore, the overall goal of this dissertation study was to 1) identify 
novel ECM regulators of angiogenesis and 2) apply our findings to understand their role 
in  cancer.  To  this  end,  the  two  main  subjects  of  this  dissertation  study  are  1) 
understanding the specific role for Matrix Gla Protein (MGP), an ECM protein, in the 
context of vascular development, angiogenesis, and cancer and 2) advancing our previous 
knowledge on another ECM protein Lumican concerning its role in cancer angiogenesis 
and metastasis are. Although the actual research study on MGP and Lumican will not be 
discussed until chapter III, my goal in this chapter is to introduce several topics that need 
to be understood to understand the research study that will be discussed in chapters III 
and IV. 
Angiogenesis: An Overview  
Vascular  network  in  our  body  is  formed  by  two  distinct  processes:  
vasculogenesis and angiogenesis [70]. During vasculogenesis, a primary capillary plexus 
is  formed  from  angioblast  cells  that  originate  from  mesodermal  cell  lineage  during 
embryonic development. However, the new vascular networks during the later stages of 
embryonic  development  and  adult  life  are  solely  formed  by  angiogenesis  [18,  70]. 
Normally in the adults, existing vasculature is stable and quiescent, held in stasis by a 
balance between pro- and anti-angiogenic molecules present in the vascular the basement 
membrane  and  surrounding  stroma  [47,  71,  72].  However,  during  specific  conditions 
such as tissue injury, exercise, and during pregnancy and the menstrual cycle in women, 
angiogenesis builds new vessels to repair injured tissue and fulfill other physiological 
needs  [73].  Angiogenesis  also  occur  under  pathological  conditions  such  as  cancer, 
inflammation, age-related macular degeneration, and others [59].  In these circumstances,      
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increasing  pro-angiogenic  stimuli  (such  as  VEGF  and  FGF)  present  in  the  nearby 
avascular  microenvironment  upsets  angiogenic  homeostasis  [74,  75]  and  activates 
endothelial cells by binding to specific receptors present on the cell surfaces [76].  
Upon  activation,  endothelial  cells  begin  to  loose  their  cell-to-cell  adhesions, 
proliferate,  dedifferentiate,  and  sprout  from  the  inner  wall  of  the  vessels  toward  the 
avascular microenvironment [66]. In the process, endothelial cells release proteases to 
digest the ECM (ECM) and clear its passage while sprouting [77-79]. Two distinct types 
of cells, namely the tip cells and stalk cells coordinate endothelial sprouting. Tip cells are 
leader cells that can move along the angiogenic gradient, and stalk cells are the follower 
cells that are more stable and quiescent and that align adjacent to tip cells forming an 
angiogenic sprout. Distinct cellular and molecular interactions determine the fate of these 
cell types [80].   
During  the  terminal  phase  of  angiogenesis,  endothelial  cells  resume 
differentiation and cease extraneous sprouting, organize themselves to form a tubular 
structure,  reconstitute  a  the  basement  membrane,  recruit  mural  cells  (pericytes  and 
vascular  smooth  muscle  cells),  re-establish  cell-cell  junctions,  and  return  to  cellular 
quiescence to form a stable vasculature [70]. A number of molecules have been identified 
to be positive and negative regulators of angiogenesis, and interestingly, a number of 
these  regulators  are  resident  within  the  ECM  present  in  the  vascular  tissues  and 
surrounding stroma [42, 81-83].  An overall angiogenesis process is illustrated in Figure 
1.       
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Regulators of Angiogenesis 
VEGF Signaling  
Vascular  endothelial  growth  factor  (VEGF)  is  a  key  regulator  of  both 
physiological  as  well  as  pathological  angiogenesis  [84].  Many  positive  regulators  of 
angiogenesis have been identified both in the tumors and in the normal tissues since the 
discovery of neovessel formation in transplanted tumors [72], but studies suggest that 
VEGF  is  one  of  the  major  limiting  factors  during  angiogenesis  [85-87].  Importantly, 
VEGF receptor is expressed in the early vascular cell lineages and initiates embryonic 
angiogenesis. VEGF (also VEGF-A) belongs to a gene family that comprises of placental 
growth factor (PLGF), VEGFB, VEGFC, and VEGFD [88]. VEGF receptors belong to 
receptor tyrosine kinase (RTK) family of receptors and comes in various types: VEGFR 
1,  2,  and  3  and  co-receptors  Neuropilin-1  and  Neuropilin-2.  VEGF-A  stimulates 
angiogenesis  through  VEGFR1  and  VEGFR2.  VEGF-A  binds  to  its  co-receptor 
Neuropilin-1 and this binding increases VEGF-A binding affinity to VEGFR2 thereby 
enhancing  VEGF-A  stimulation  of  angiogenesis.  Therefore,  VEGFA-VEGFR1/2  has 
become  an  attractive  pharmaceutical  target  for  angiogenesis  inhibition  in  various 
diseases.  VEGF-A  is  also  an  embryonic  stimulator  of  angiogenesis  that  promotes 
endothelial  progenitor  differentiation  and  endothelial  cell  growth,  survival,  migration, 
and tubular formation [75, 85, 88]. Mice lacking a single allele of VEGF (-/+) showed 
severe defects in early angiogenesis, such as failure of aortic connection to the heart and 
poor development of dorsal aorta [89, 90]. Despite the heterozygotic lethality being very 
rare among mammals, VEGF -/+ lethality in mice suggests that appropriate concentration 
of VEGF is essential in the development of functional circulatory system in embryos.       
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Under  normoxic  conditions,  VEGF-A  expression  is  known  to  be  under  the 
transcriptional  control  of  Fos/Jun  complex,  nuclear  factor  kappa  B  (NFkB),  and 
hormones such as estrogen [91-93]. However, under hypoxic condition VEGF-A gene 
expression  is  controlled  by  hypoxia-inducible  factor  complex  [94].  VEGF-A  gene 
contains hypoxia responsive element (HRE) site, which binds to HIF complex and induce 
VEGF-A gene expression [95]. In addition, hypoxic condition is also known to stabilize 
VEGF-A  mRNA  post-transcriptionally  and  enhances  translation  to  VEGFA  protein. 
Other forms of VEGF also regulate angiogenesis and their operation is mainly context 
dependent. For instance, VEGF-C/D stimulates Lymphangiogenesis through VEGFR3. 
VEGF-B activates VEGFR1 and is commonly expressed in tissues such as heart and 
skeletal  muscle.  To  sum  up,  VEGF/VEGFR  signaling  is  primary  regulators  of 
angiogenesis.  
Notch Signaling 
In humans, Notch signaling operates via four notch receptors, Notch 1 to 4, and 
five ligands, namely jagged 1-2 and Dll1, Dll3, and Dll4. Notch signaling can be initiated 
by  either  adjacent  heterologous  ligand-expressing  cells  or  by  the  same  cell  (Notch 
autonomous signaling). Upon ligand binding, a proteolytic processing (S1, S2, S3) on the 
notch receptors releases an intracellular domain of Notch (NICD). NICD translocates into 
the  nucleus  and  associates  with  the  CSL  family  of  binding  proteins  and  become 
transcriptional activator, which turns on transcription of a set of target genes, including 
notch responsive promoters such as HRT, Hes-1, Hey-1, Hes-5. Most of the notch-target 
genes are transcription regulators of tissue-specific helix-loop-helix transcription factors. 
Notch signaling also activates its target gene via NF-kB [96].       
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Notch  signaling  is  a  critical  regulator  of  angiogenesis  particularly  during 
sprouting and stabilization of vascular lumen [97, 98]. Two distinct notch ligands work in 
an opposing manner to control angiogenic sprouting [80]. Notch ligand DLL4 “switches 
off” angiogenic signal and makes endothelial cells irresponsive to VEGF signaling. As a 
result, DLL4 suppresses endothelial sprouting and vessel branching [99] and promotes 
stable vascular lumen formation [97]. In contrast, notch ligand Jagged-1 functions as 
angiogenic “switch on” signal that antagonizes DLL4 function and enhances endothelial 
sprouting [80]. This opposing effect of DLL4 and Jagged-1 is due to their ability to 
regulate  the  differentiation  of  endothelial  cells  into  leading  tip  cells  vs.  stalk  cell 
phenotype  [80].  DLL4  promotes  endothelial  cell  differentiation  into  more  stable  and 
quiescent stalk cell phenotype, whereas jagged-1 promotes endothelial differentiation into 
leading  tip  cell  phenotype.  Tip  cells  exist  as  filapodia-like  projections  extended  and 
pointed toward the angiogenic stimuli and migrate in the same direction to form the 
extending  sprouts.  Therefore,  jagged-1  and  DLL4  activation  oppose  each  other  to 
maintain  a  stasis  between  leading  tip  cell  vs.  quiescent  stalk  cell  phenotypes  during 
angiogenic sprouting. Differential role of notch ligands DLL4 and Jagged-1 is illustrated 
in Figure 2.  
Besides  its  role  in  sprouting  angiogenesis,  notch  signaling  also  controls  other 
aspects of vascular development including arterial/venous specification [100, 101] and 
vascular  mural  cell  function  [102].  During  embryonic  development,  notch  expression 
promotes  endothelial  differentiation  into  arterial  vessels  and  suppresses  the  venous 
identity.  Mural  cells  such  as  pericytes  also  provide  signals  to  stop  endothelial 
proliferation  and  sustain  survival,  which  are  requisite  for  vascular  stability  [103].      
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Recruitment  of  Mural  cells  by  nascent  vessels  is  heavily  dependent  upon  notch 
receptor/ligand interaction between endothelial cells and mural cells [104]. Similar notch 
system  regulates  angiogenesis  in  tumors  as  well,  and  notch  presents  an  attractive 
therapeutic target in restricting angiogenesis in tumors [102, 105, 106]. 
BMP Signaling 
Bone morphogenetic proteins (BMPs) belong to TGFbeta superfamily of secreted 
proteins and BMP signaling is critical during embryogenesis, tissue morphogenesis and 
homeostasis. BMP signaling is similar to that of TGFbeta signaling in that it is smad 
dependent.  Like  TGFbeta,  BMP  binds  to  specific  type  II  receptor  and  recruit  type  I 
receptor (ALK 1, 2, 3, and 6) and leads to phosphorylation of specific receptor smads (R-
smads). Endoglin (CD105) and Betaglycan (TGFBR3) are co-receptors for BMPs. Unlike 
TGFbeta, BMP signaling is activated through receptor smads 1, 5, and 8. Eventually, an 
activated receptor smads complex with co-smad, smad 4, and the resulting heterocomplex 
is translocated into the nucleus where it binds to promoter of target genes and regulate 
transcription [36, 107].  
BMP is an important regulator of vascular development and angiogenesis [36]. 
For instance BMP-2/4 function is critical for vascular development, since the deletion of 
BMP-2/4 and its receptor impaired the mesodermal differentiation into vascular lineages 
and severely impacted vascular development [10, 37]. In addition, mice with smad 1 and 
5,  key  transcription  factors  for  BMP2/4,  showed  defects  in  angiogenesis  [10,  108]. 
Importantly, BMP-2 is expressed by a number of tumors and functions as key stimulator 
of  angiogenesis  in  tumors.    For  instance,  BMP-2  increased  angiogenesis  in  A549 
subcutaneous  lung  cancer  tumor  model  [109].  In  addition,  matrigel  implants      
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supplemented with BMP-2 contains more angiogenesis than the control, and the effect is 
neutralized by BMP-2 antagonist noggin. These data highlighted the importance of BMP-
2 function both in pathological, as well as in physiological, angiogenesis. Moreover, the 
angiogenic effect of BMP-2 is shown to be smad 1,5, and 8 dependent, which stimulates 
endothelial cell proliferation.  
A Cross-talk Between VEGF, Notch, and BMP Signaling 
A number of studies show that Notch, VEGF, and BMP signaling crosstalk to 
regulate a number of vascular functions including angiogenesis [80, 110-114]. VEGF 
activates notch ligand DLL4 in the endothelial tip cells. During sprouting, the expression 
of DLL4 in the tip cells activates notch in the adjacent stalk cells and suppresses jagged-1 
expression in the stalk cell. In the absence of DLL4, VEGF stimulation elevates jagged-1 
expression  in  the  stalk  cells,  which  increases  VEGF-R2  expression  in  the  adjacent 
endothelial cells and initiate sprouting [80, 115]. Therefore, loss or suppressed DLL4 
function elevates inappropriate angiogenic response with increased vessel branching and 
loss of vascular lumen formation. Therefore, two distinct notch ligands crosstalk with 
VEGF signaling to balance angiogenesis. Consequently, blockade of DLL4 expression in 
tumors produced highly branched and dysfunctional vessels and suppressed tumor growth 
due to non-functional angiogenesis [97, 106, 112, 116]. Interestingly, tumors are found to 
elevate  DLL4  expression  in  a  VEGF-dependent  manner  to  enhance  productive 
angiogenesis [112]. Besides its direct effect on endothelial cells, VEGF/notch crosstalk is 
also critical in mural cell function and stabilization of the vascular wall. Collectively, 
these findings emphasize the importance of notch signaling during vascular development 
and angiogenesis.       
 
23 
A  crosstalk  with  VEGF  signaling  is  essential  for  BMP  in  its  regulation  of 
angiogenesis  and  other  vascular  functions.  For  instance,  BMP  stimulates  VEGF-A 
production  in  differentiating  osteoblasts  to  stimulate  angiogenesis  during  bone 
development [113]. BMP-9 has been shown to stimulate endothelial cell proliferation via 
VEGF-VEGFR2  signaling  and  has  been  shown  to  enhance  in-vivo  angiogenesis  in  a 
matrigel implant and in the human pancreatic xenograft tumor model [114]. Interestingly, 
however,  other  studies  show  BMP2  regulate  angiogenesis  independent  of  VEGF-
A/VEGFR  signaling  pathway  [3,  8].  For  instance,  in  the  zebrafish,  BMP  stimulates 
venous angiogenesis via BMP/Bmpr/2/Alk2/3/smad/Erk pathway independent of VEGF 
signaling. On the other hand, arterial angiogenesis from the dorsal aorta is strictly under 
the control of VEGF stimulation. [117]. Therefore, BMP regulates angiogenesis either 
with or without crosstalk with VEGF in a context-dependent manner.  
Besides its interactions with VEGF signaling, BMP also involves notch signaling 
in its regulation of varieties of vascular function including angiogenesis. Studies show 
that Notch signaling being a requisite for BMP function in the induction of osteogenic 
differentiation  and  mineralization  of  vascular  smooth  muscle  layer  [118,  119].  Most 
importantly,  BMP  also  depends  on  notch  function  for  its  angiogenic  activity.  For 
example,  a  study  showed  that  the  stalk  cell  phenotype  of  endothelial  cells  during 
angiogenesis is dependent upon the cooperative action of notch and BMP signaling [111]. 
Collectively, angiogenesis is a complex process and its regulation is under the control of 
various signaling mechanisms that work in cooperation of each another (see figure 3).      
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ECM and Angiogenesis 
ECM  is  a  critical  regulator  of  vascular  development.  During  embryonic 
development, ECM develops around differentiated endothelial cells. ECM proteins such 
as Fibronectin, Laminin, and Collagen are very prominent around endothelial layer and 
provide adhesive support to growing endothelial cells and help mature into a primary 
capillary plexus [18]. Furthermore, ECM also helps to maintain vascular homeostasis, 
morphogenesis,  remodeling,  and  angiogenesis  during  adult  life  [120-122].  During 
angiogenesis, ECM (ECM) not only provides a scaffold to the growing endothelial cells, 
but it also contains distinct angiogenic signals to initiate, drive, and complete angiogenic 
process  [50,  121].  Moreover,  ECM  manipulates  angiogenic  growth  factors  (such  as 
VEGFs and FGFs) by regulating their release, binding, and activation [68, 123]. 
ECM binding with integrins lies central to endothelial cell-matrix interactions.  
ECM also controls endothelial cell behavior through its interaction with integrin [16, 50, 
124, 125]. A number of ECM molecules, including Collagen, Fibronectin, Proteoglycan, 
and Laminin, bind to integrin receptors present on the surface of endothelial cells and 
control neovessel formation.  ECM interactions with integrins promote focal adhesion 
and,  in  the  absence  of  proper  ECM-integrin  interaction,  endothelial  cells  lose  focal 
adhesion and undergo apoptosis through a p53 dependent pathway [126]. As a result, a 
subset of ECM binding integrins is upregulated during angiogenesis. Interestingly, VEGF 
is also found to increase the expression of a1B1 and a1B2 integrin in microvasculature, 
suggesting that VEGF-induced integrin is essential during angiogenesis [127].  
ECM also regulates angiogenesis through its pro-and-anti-angiogenic activities on 
endothelial cells [69, 75]. For instance, several ECM fragments that are derived from      
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collagens,  including  endostatin,  tumstatin,  canstatin,  arresten,  and  hexastatin,  have 
stimulatory  or  inhibitory  function  on  angiogenesis  [71].  Likewise,  endorepellin,  a 
derivative  of  perlecan,  serves  as  anti-angiogenic  agent.  Furthermore,  the  basement 
membrane restricts angiogenesis, and its degradation is requisite for angiogenesis. As a 
result,  endothelial  cells  increase  the  expression  of  ECM-degrading  enzymes  such  as 
membrane  type-matrix  metalloproteinases  (MT-MMP)  during  angiogenesis  [77]. 
Therefore,  coordinated  degradation  of  ECM—both  the  basement  membrane  and 
interstitial  matrix—by  matrix  metalloproteinases  is  essential  in  the  initiation  of 
angiogenesis  [47],  whereas  its  re-establishment  is  critical  in  the  resolution  phase  of 
angiogenesis. Collectively, ECM provides a foundation to initiate, grow, and complete 
angiogenesis.  Therefore,  a  more  complete  understanding  of  ECM  function  and  its 
regulators is urgent in the design of better angiogenic therapeutics to treat diseases due to 
abnormal angiogenesis.   
Tools Used To Discover Novel ECM Regulators of Angiogenesis 
To  successfully  identify  and  characterize  the  novel  ECM  regulators  of 
angiogenesis, we need appropriate tools in hand. In this study, I have utilized modern cell 
and molecular techniques (cell culture, transfection, western blot, RT-PCR, luciferase 
reporter assay etc), morpholino based gene knockdown in a transgenic fli-1
GFP/GATA-
1
RFP zebrafish model for vascular development and angiogenesis, ex-vivo tissue culture 
model of angiogenesis (Aortic Ring Assay), specific ECM gene knockout mouse model 
systems, and transgenic cancer cell line models to achieve my research goals. In the 
following section, I will provide a review of the Microarray and Transgenic Zebrafish 
model used for the angiogenesis study.        
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Microarray: Identification of Novel ECM Regulators of Angiogenesis 
Microarray  experiments  have  led  us  to  identify  novel  ECM  regulators  of 
angiogenesis.  Microarray  is  a  high-throughput  system  that  allows  us  to  monitor  the 
expression  of  multiple  genes  simultaneously.  A  DNA  microarray  system  contains 
specific sequences of DNA from various genes known as probes that are attached to the 
solid surface called biochips. Fluorescently labeled complementary DNAs from various 
samples can be hybridized to the known DNA probes in the chip to determine mRNA 
expression, and the expression can be quantified based on the intensity of the labeled 
fluorescence.  
We have identified differential expression patterns for a number of genes from a 
microarray experiment on mRNA extracted from MB114 endothelial cells undergoing in-
vitro angiogenesis on matrigel matrices at 1 hr, 5 hr, 15 hr, and 25 hr period [83].  Our 
results  identified  a  number  of  genes  that  were  previously  known  to  be  angiogenic 
regulators. and we also identified a number of other new genes that were differentially 
regulated during the in-vitro angiogenesis. Among these novel genes were secreted ECM 
proteins such as Matrix Gla Protein (MGP) and Lumican (See figure 4). 
Transgenic Zebrafish Model of Angiogenesis  
We have utilized transgenic zebrafish model of angiogenesis as one of the tools to 
study angiogenic effect of newly identified ECM molecules. The transgenic zebrafish is 
produced by fusing GFP with a blood vessel specific Fli-1 promoter and fusing RFP with 
a  blood  cell  specific  GATA1  promoter.    The  double  transgenic  Fli-1
GFP/GATA1
RFP 
zebrafish is obtained by breeding Fli1
GPF with GATA1
RFP. The resultant GFP and RFP 
transgenic fish is a great tool to study vascular development and angiogenesis because it      
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allows us to visualize the blood vessels (GFP) and the blood flow (RFP) in real time 
under fluorescent microscope during vascular development in zebrafish.  
Morpholino  based  gene  knockdown  system  is  utilized  in  these  transgenic 
zebrafish by injecting morpholinos specific to ECM proteins to study ECM function in 
vascular  development  and  angiogenesis.  Morpholinos  are  synthetic  oligonucleotides 
similar  in  structure  to  DNA  molecules  that  binds  to  mRNA  and  blocks  mRNA’s 
translation to protein. Thus, morpholino injections block the expression of ECM proteins 
in  the  zebrafish.  Thus,  coupling  morpholino  based  gene  knockdown  system  and 
transgenic Fli1
GFP/GATA1
RFP zebrafish makes it easier and efficient tool to screen novel 
ECM molecules for their roles in vascular development and angiogenesis.  
Matrix Gla Protein (MGP): A Literature Review 
Matrix Gla protein (MGP) was first identified in bovine bone and contains gam 
ma-carboxylated glutamine residues [128]. The glutamine residues are carboxylated at 
NH2-terminal by gamma-carboxylase in a vitamin-K dependent manner. Therefore, MGP 
is a vitamin-K dependent protein. MGP has a sequence homology with Bone Gla Protein 
(BGP), and these two proteins are believed to have evolved through gene duplication and 
subsequent divergent evolution [129]. Analysis from rat bone development revealed that 
MGP accumulation in the bone appeared much earlier than BGP and that MGP levels 
among  newborn,  juvenile,  and  adult  rats  were  similar.  These  findings  from  rat  bone 
indicate  that  MGP  function  is  critical  in  the  early  bone  development.  Transcriptome 
analysis show MGP is highly expressed in the Lung, Heart, and Kidney [130]. 
In  humans,  MGP  gene  comprises  3.9  kilobases  of  chromosomal  DNA  and  is 
located in the shorter arm of chromosome 12 (12p) [131]. MGP gene is comprised of four      
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exons separated by three introns and is present as a single copy. Besides TATA and CAT 
boxes, MGP gene promoter is comprised of a number of putative regulatory sequences 
for hormone and transcription factors including binding sites for retinoic acid and vitamin 
D.  In  rat  vascular  smooth  muscle  cells,  transcription  of  MGP  gene  is  found  to  be 
downregulated by retinoic acid and TGFbeta and upregulated by vitamin D3 and cyclic 
AMP  [132].  In  addition,  MGP  promoter  also  contains  a  binding  site  for  RunX2,  a 
primary  transcription  factor  involved  in  bone  development,  and  RunX2  is  shown  to 
control MGP expression in A6 cells. Furthermore, an additional exon in the 5’ region 
containing calcium-sensitive promoter is found in Xenopus laevis [133], suggesting a 
complex transcriptional regulation of MGP gene. MGP is expressed as an 84-residue (~ 
10 kD) vitamin K dependent protein. MGP protein sequence comprises transmembrane 
signal peptide, carboxylation site, and Gla-containing domain in the N-terminal region. 
MGP is secreted into ECM upon its synthesis.  MGP is almost ubiquitously expressed in 
human tissues including vascular tissues [134].  
MGP  function  in  mediating  cellular  adhesion  to  ECM  is  known  [135]  and  it 
promotes cellular adhesion through its Gla domain [135]. Antibodies against the non-gla 
domain  did  not  affect  adhesion,  but  the  removal  of  Gla  residues  or  its  inhibition  by 
synthetic peptide significantly inhibited the cellular adhesion, suggesting that Gla domain 
is solely responsible for its function in cellular adhesion. Purified MGP from bovine bone 
was  shown  to  adhere  to  various  cell  types  including  chondrocytes,  fibroblasts, 
osteosarcoma  cells,  and  kidney  mesangial  cells.  Interestingly,  MGP  is  also  shown  to 
interact  with  vitronectin,  a  component  of  ECM,  through  a  specific  domain  in  its  C-
terminal region [136]. MGP interactions with vitronectin are prominent in embryonic      
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tissues, suggesting a critical role for MGP in the modulation of cell-matrix interactions 
during development. Besides vitronectin, MGP peptide is also shown to interact with 
fibronectin. MGP interactions to extracellular component is most likely very specific to 
vitronectin and fibronectin since it did not bind to other components of ECM including 
collagen, laminin, fibromodulin, heparin, Osteocalcin, and chondroitin sulfate. Sequence 
analysis  showed  no  similarity  in  the  sequences  between  MGP  and  other  ECM-based 
cellular  adhesion  proteins  such  as  fibronectin,  laminin,  vitronectin,  fibrinogen,  von 
Willebrand factor (vWf), entactin, thromospondin, collagen type I, and collagen type IV. 
These data suggest that MGP may have a unique physical and biochemical properties 
from other ECM component.   
Although MGP has some role in cellular adhesion, its primarily known as an 
inhibitor  of  tissue  mineralization  [137].  MGP  is  heavily  expressed  by  growth  plate 
cartilage and inhibition of MGP cause excessive growth plate mineralization and thus 
growth retardation. This effect was observed in rats treated with Warfarin, a vitamin K 
antagonist. A similar disorder is also observed in infants whose mothers were subjected 
to Warfarin during pregnancy. In humans, MGP deficiency causes Keutal Syndrome, a 
disease syndrome collectively resulting in calcification of cartilages, pulmonary stenosis, 
and mid-face hypoplasia [138]. One of the ways by which MGP inhibits mineralization is 
via inhibition of calcification since MGP directly interacts with hydroxyapatite crystals, a 
form  of  calcium  deposit  in  tissues  [139].  MGP  also  inhibits  BMP  2/4  signaling  and 
suppresses BMP induced chondrogenic and osteogenic differentiation in cartilages and 
bone tissues respectively [140].       
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MGP is heavily expressed in vascular tissues [134], and it plays a critical role in 
maintaining  vascular  function.  For  instance,  mice  deficient  in  MGP  (MGP-/-)  show 
severe calcification of aorta and die within 2 months possibly due to damages in vascular 
system [141]. MGP also suppresses mineralization of vascular tissues and prevents from 
arteriosclerosis and atherosclerosis in arterial vessels [31].   Furthermore, MGP is also a 
critical  regulator  of  artery-venous  formation  since  MGP  deficiency  in  mice  caused 
arteriovenous malformation [117]. In addition, polymorphism in MGP gene is associated 
with a number of cardiovascular dysfunctions including coronary artery calcification and 
vascular damages in chronic kidney diseases [142, 143].  
Although the primary function of MGP in vascular tissues is associated with its 
function as a calcification inhibitor, it has also been described as a critical regulator of 
endothelial cell function. For instance, MGP expression is significantly increased during 
the angiogenesis process [83] and it has been shown to regulate both physiological as 
well as tumor angiogenesis [144, 145]. MGP function in vascular tissues is attributed to 
its ability to interact with BMP 2/4 and inhibit BMP function [31, 146-149]. BMP 2/4 is 
previously  characterized  as  an  angiogenesis  stimulator  [3,  109],  and  its  inhibition  by 
MGP would suggest MGP to be an anti-angiogenic agent. In contrast, a number of other 
studies show MGP as pro-angiogenic molecule [144, 145]. Despite these conflicting data, 
an in-depth study to pinpoint the mechanistic details of MGP function during angiogenic 
process is still lacking.  Therefore, one of the main objectives of this dissertation study is 
to evaluate the role for MGP and its underlying molecular mechanism in the context of 
angiogenesis both in normal as well as in tumor tissues. The findings for MGP from this 
study will be discussed in detail later in chapter III.       
 
31 
Lumican: A Literature Review 
Lumican is an extracellular matrix protein belonging to a family of small leucine-
rich proteoglycans (SLRPs). Lumican expression in human tissues is widespread and 
commonly found in cornea and dermal layer of skin. Human Lumican gene is localized in 
chromosome 12 (12q21.3-q22). Lumican core protein contains 338 amino acid residues 
and  share  features  common  to  small  leucine-rich  proteoglycans.  It  contains  leucine 
repeats in the central domain flanked by N-terminal and C-terminal domains containing 
highly conserved cysteine residues. The Lumican core-protein contains 4 distinct sites for 
N-glycosylation, and some of these sites are substituted by keratan sulfate side chains.  
Therefore, Lumican is commonly called a keratan sulfate proteoglycans and exist as a 55-
57 kDa proteoglycan in tissues. Lumican is a substrate for a number of matrix proteases 
including MT1-MMP, MMP-12, and ADAMTS-4 (Ref 34-35). Lumican is homologous 
to other member of SLRP family proteins such as decorin and fibromodulin and has 
shared  function  with  fibromodulin  in  the  organization  of  collagen  fibril.  Details  on 
Lumican core protein structure and Lumican gene is reviewed in [150, 151].  
Primarily, Lumican is known as a regulator of collagen fibrillogenesis [152]. It is 
highly  expressed  in  the  cornea  and  is  a  critical  regulator  of  corneal  collagen 
fibrillogenesis [153]. Proper assembly of collagen is essential for corneal transparency 
and a study show that Lumican knockout (Lum -/-) mouse exhibits corneal opacity [154]. 
Lumican deficiency also causes loose skin. These data suggest that Lumican function is 
indispensible  in  proper  organization  of  collagen  in  tissues  and  its  proper  function  is 
highly critical in maintaining extracellular dynamics in tissues since collagen is one of 
the most abundant components of ECM.       
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Although  initially  identified  in  the  corneal  stroma,  Lumican  expression  is 
ubiquitously  found  in  various  tissues  including  heart,  lung,  intestine,  bone,  articular 
cartilage, pancreas, placenta, kidney, breast, brain, cervix, colon, liver, smooth muscle, 
and  uterus  [155-161].  Therefore,  a  proper  functioning  of  Lumican  is  critical  in 
maintaining tissue homeostasis and consequently its defect have been implicated in a 
number  of  diseases  including  cancer.  Lumican  expression  is  significantly  altered  in 
various  cancers.  However,  the  description  of  Lumican’s  role  in  cancer  is  based  on 
correlation data at the best. For instance, compiled expression data from various breast 
cancer  patients  show  high  level  of  Lumican  expression  correlates  with  higher  tumor 
grade in breast cancer.
2 Consistently, increased level of Lumican expression in tumors is 
also shown to lower long-term survival in breast cancer.
3 These expression data from 
breast  cancer  suggested  that  Lumican  promotes  tumor  growth  and  progression.  In 
contrast,  ectopic  expression  of  Lumican  in  various  cancer  including  pancreatic 
adenocarcinoma, fibrosarcoma, and B16 melanoma is previously shown to reduced tumor 
growth and angiogenesis, suggesting an anti-tumorigenic role for Lumican [42]. Most 
importantly, Lumican is previously shown to induce apoptosis in endothelial cells and 
suppressed  tumor  angiogenesis  suggesting  that  anti-tumorigenic  role  for  Lumican  in 
some of these tumors is due to its anti-angiogenic activity. In addition, anti-angiogenic 
activity of Lumican has been previously described in other contexts [162] including in-
vitro model of angiogenesis [83].  
                                                 
2 www.oncomine.org 
3 www.kmplot.com      
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Unfortunately, these findings on Lumican and its role in cancer and angiogenesis 
are solely based on either correlative expression data or the measurement of its effect due 
to  ectopic  expression.  However,  the  anti-tumorigenic  and  anti-angiogenic  role  for 
endogenous Lumican has not been measured directly. In addition, previous studies have 
shown  that  Lumican  promotes  wound  healing  of  corneal  and  skin  epithelium.  This 
finding raises another question that is whether Lumican has pro-angiogenic effect in the 
physiological setting. Therefore, this dissertation aimed to further elaborate on the roles 
of  Lumican  to  delineate  its  differential  function,  if  any,  from  endogenous  versus 
exogenous expression in both physiological versus pathological context. The findings 
from Lumican will be discussed in detail in chapter IV.  
Summary  
From  the  review  in  this  chapter,  I  highlighted  angiogenesis  as  an  important 
process of vascular development and defect in angiogenesis can lead to serious vascular 
abnormalities during development as well as in adult life. In addition, I also rationalized 
the  need  for  the  novel  angiogenic  regulators  since  the  ones  that  we  identified  as 
prominent  angiogenesis  regulators  such  as  VEGF  could  not  develop  into  a  reliable 
therapeutic target for angiogenesis. To this end, we needed to look for a better therapeutic 
target, and ECM is a prominent source for angiogenic regulators. We have also identified 
a number of ECM based regulators of angiogenesis. Among these newly identified ECM 
regulators of angiogenesis, I studied MGP and Lumican for their role in angiogenesis and 
cancer.     
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Figure 1. Angiogenesis is a complex multi-step process. 
Step 1: An avascular tissue (tumor as an example shown here) when requires 
angiogenesis  releases  angiogenic  factors  such  as  VEGF,  FGF,  and  others  to  its 
surrounding. The angiogenic factors reach to nearby blood vessels. Step 2: Angiogenic 
factors interact with endothelial cells lining the blood vessels through endothelial cell 
surface receptors specific for the angiogenic factors. Upon these interactions between 
endothelial cell surface receptor and corresponding angiogenic factor, endothelial cells 
becomes  activated  and  initiates  angiogenic  process  (initiation  phase).  Initiation  phase 
proceeds to Step 3: Elongation phase and ultimately to step 4: resolution phase.  Critical 
steps occurring during each steps is shown in colored text boxes.         
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Figure 2. Differential notch signaling regulates angiogenic sprouting: DLL4 and Jagged-
1 has an opposing effect. 
Shown here is a representation of notch activation via two distinct notch ligands 
DLL4  and  Jagged-1,  which  exert  an  opposing  effect  during  sprouting  angiogenesis. 
DLL4  suppresses  endothelial  sprouting  and  promotes  endothelial  quiescence  and 
promotes lumen formation. Whereas jagged-1 promotes sprouting of endothelial cells 
and inhibits vessel quiescence and thus suppresses lumen formation. Shown in the figure 
right  hand  side,  Jagged-1  promotes  angiogenic  tip  cells  whereas  DLL4  promotes 
quiescent follower stalk cells. A balance between these two distinct cell types is critical 
during the formation of productive angiogenesis and thus the balance act of these two 
opposing  notch  ligands  produce  a  functional  new  vessel  sprout.      
 
36 
 
Figure 3. The crosstalk between VEGF, notch, and BMP signaling in the regulation of 
angiogenesis. 
  Shown here is a complex interaction between three distinct signaling mechanisms 
VEGF, notch, and BMP signaling where notch controls angiogenesis sprouting via two 
distinct  notch  ligands  interaction  to  adjacent  endothelial  cells.  VEGF  signaling  also 
initiates notch activation in endothelial cells. Like wise, BMP can activate both VEGF 
and  notch  signaling  in  the  regulation  of  angiogenesis.  BMP  and  VEGF  can  activate 
angiogenesis  independent  of  each  other  or  notch  signaling  as  well.  Therefore, 
angiogenesis regulation by VEGF, notch, and BMP is a collective effort from VEGF, 
notch,  and  BMP  signaling  and  tightly  controls  a  complex  multi-step  angiogenesis 
process.      
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Figure  4.  The  microarray  experiment  used  to  identify  MGP  and  Lumican  as  regulators  of 
angiogenesis.   
  MB114  endothelial  cells  were  induced  to  undergo  tube  formation  (an  in-vitro 
angiogenesis  model).  During  the  course  of  tube  formation,  total  RNA  was  collected  from 
endothelial cells at 1, 5, 15, and 25 hours. RNA collected at 1 hour (labeled green) is mixed in 
equal quantity with that from 5 hours, 15 hours, and 25 hours labeled red separately. Each 
mixture  of  RNA  was  hybridized  with  microarray  biochip  (Affymetrix  MOE430A  array) 
containing cDNA and the expressions of genes were determined based on the intensity of green 
(decreased expression), yellow (equal expression), and red (increased expression) fluorescence 
as detected by computerized detection system. Such microarray analysis of in-vitro model of 
angiogenesis (tube formation assay) revealed significant increased in the expression of MGP 
and Lumican and their expression levels are shown in the table to the right.       
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CHAPTER III 
MATRIX GLA PROTEIN (MGP) REINFORCES ANGIOGENIC RESOLUTION 
 
Abstract 
Matrix  Gla  Protein  (MGP)  is  an  ECM  molecule  commonly  associated  with 
dysfunctions of large blood vessels such as arteriosclerosis and atherosclerosis.  However, the 
exact role of MGP in the microvasculature is not clear.  Utilizing a mouse MGP knockout 
model  we  found  that  MGP  suppresses  angiogenic  sprouting  from  mouse  aorta,  restricts 
microvascular density in cardiac and skeletal muscle, and is an endogenous inhibitor of tumor 
angiogenesis.  Similarly, morpholino based knockdown of MGP in zebrafish embryos caused a 
progressive loss of luminal structures in intersegmental vessels, a phenotype reminiscent of 
Dll4/Notch  inhibition.   Accordingly,  MGP  suppressed  Notch-dependent  Hes-1  promoter 
activity expression of Jagged1 mRNA relative to Dll4 mRNA.  However, inhibition of BMP 
but  not  Notch  signaling  reversed  the  excessive  angiogenic  sprouting  phenotype  of  MGP 
knockout aortic rings suggesting that MGP may normally suppress angiogenic sprouting by 
blocking BMP signaling.  Collectively, these results suggest that MGP is a multi-functional 
inhibitor of normal and abnormal angiogenesis that may function by coordinating with both 
Notch and BMP signaling pathways. 
Keywords: Angiogenesis/ ECM/ Matrix Gla Protein/Notch Signaling/ BMP signaling/ 
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Introduction 
Angiogenesis  is  the  development  of  new  capillaries  from  pre-existing  vessels. 
Normally, existing vasculature is stable and quiescent, held in stasis by a balance between pro- 
and anti-angiogenic molecules present in the vascular basement membrane and surrounding 
stroma.  During  angiogenesis,  however,  increasing  pro-angiogenic  stimuli  present  in  the 
microenvironment  upsets  this  balance  and  activates  angiogenesis  by  binding  to  specific 
receptors present on endothelial cell surfaces. Upon activation, endothelial cells begin to loose 
their  cell-to-cell  adhesions,  proliferate,  dedifferentiate,  and  sprout  toward  the  avascular 
microenvironment.  During  the  terminal  phase  of  angiogenesis,  endothelial  cells  re-
differentiate,  cease  extraneous  sprouting,  organize  themselves  to  form  tubular  structures, 
reconstitute a basement membrane, recruit mural cells (pericytes and vascular smooth muscle 
cells),  re-establish  cell-cell  junctions,  and  return  to  cellular  quiescence  to  form  a  stable 
vasculature [86].  
Inappropriate angiogenesis is involved in the pathogenesis of several diseases including 
cancer  [58-60,  163].  Therefore,  therapeutic  manipulation  of  angiogenesis  represents  an 
attractive  approach  for  the  treatment  of  these  diseases.  In  order  to  improve  angiogenic 
therapeutics however, the identification of both pro as well as anti-angiogenic molecules and 
characterization of their mechanism of action is important. Interestingly, ECM (ECM) not only 
provides  a  scaffold  to  the  growing  endothelial  cells  but  also  contains  distinct  angiogenic 
signals to initiate, drive, and complete angiogenic process [50, 121]. Indeed, several ECM 
(ECM) molecules have been identified as angiogenic regulators [16, 17, 64, 164]. Therefore, 
the  complete  characterization  of  ECM-based  angiogenic  molecules,  and  the  molecular      
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mechanism  by  which  these  molecules  regulate  angiogenesis  represents  an  important,  yet 
underdeveloped avenue towards potential angiogenic-based therapeutics.  
Matrix Gla Protein (MGP) is an ECM molecule commonly found near vascular tissues 
[31, 141, 165]. Primarily, MGP has been described as a calcification inhibitor and is crucial for 
the maintenance of normal vascular function [141, 146]. For example, MGP -/- mice show 
severe aortic calcification and uniformly die within two months of birth [141]. In addition, 
MGP polymorphisms have been linked to coronary artery calcification [143, 166], and MGP 
suppresses the formation of atherosclerotic lesions in the apolipoprotein E (APOE) knockout 
mouse  model  of  human  atherosclerosis  [31].  Mechanistically,  MGP  sequesters  BMP2  and 
BMP4, thereby blocking BMP signaling through ALK receptors [149]. However, it is not clear 
whether MGP suppresses vascular calcification via inhibition of BMP signaling alone or if 
additional mechanisms may be involved. In light of this, a recent discovery suggested that 
BMP  alone  is  insufficient  to  promote  smooth  muscle  calcification.  Rather,  BMP  requires 
cooperation with the notch signaling pathway to promote vascular calcification [118, 119].  
This observation is further supported by results showing that signaling through the BMP and 
Notch pathways synergistically suppress VEGF expression [110, 167]. 
MGP is not only physiologically important in large blood vessels, but also appears to be 
an  important  regulator  of  capillary  function  and  angiogenesis.  MGP  suppresses  excessive 
branching of pulmonary capillaries during vascular development in mice [146]. Furthermore, 
MGP is differentially expressed during angiogenesis [81, 83, 168] and is increased in tumor 
vasculature where it appears to promote tumor angiogenesis in glioblastoma [145]. Finally, 
MGP deficiency in mice has been shown to cause arteriovenous malformations in lungs and 
kidney [117]. Collectively, MGP has been broadly implicated in angiogenesis and vascular      
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biology, but its exact role in this context is unclear. Therefore, the main goal of this study is to 
investigate a more direct role for MGP during angiogenesis.  
Here, we show that MGP suppresses excessive endothelial sprouting, maintains stable 
vascular  luminal  structures,  prevents  excessive  microvascular  densities,  and  reduces  tumor 
angiogenesis. Mechanistically, we find that MGP suppresses notch signaling suggesting that 
MGP may mediate vascular quiescence at least in part by blocking BMP and notch signaling. 
Collectively,  these  results  suggest  that  MGP  re-inforces  vascular  quiescence  and  promote 
angiogenic resolution.  
Materials and Methods 
Ethics Statement 
Animal  studies  were  performed  in  accordance  with  the  animal  protocol  procedures 
approved by the Institutional Animal Care and Use Committee of Indiana State University 
(protocol #1-19-2008:AA and 11-08-2007:AA). 
Mouse Breeding and Genotyping  
MGP -/+ mice in C57BL/6 background were generously provided by Gerard Karsenty 
(Columbia  University  Medical  Center,  NY).  MGP  -/+  mice  were  crossed  with  wild  type 
C57BL/6  mice  and  the  siblings  were  crossed  to  produce  MGP  -/-  mice.  Genotype  was 
determined by PCR amplification of DNA from ear tissue using DirectPCR Lysis Reagent 
(Viagen Biotech, Inc., LA, CA). PCR was performed using specific primers targeting wild type 
vs. mutant MGP alleles. The wild type primer pairs targeted a 450 bp wild type MGP allele 
whereas the mutant primer pairs targeted a 1 Kb MGP mutant allele. Wild type and mutant 
PCR reactions were performed separately using the following conditions: 1 μl template DNA 
(from ear sample), 100 nM primers, 1X standard buffer, 320 μM dNTPs, and 66 U/ml Taq      
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polymerase (New England Bio Labs Inc.), and total volume 25 μl. Reactions were cycled 
according to the following conditions: 94
oC for 2 min (1X); [94
oC for 45 sec; 57
oC for 40 sec; 
72
oC for 60 sec] (35X); 72
oC for 5 min (1X); and 4
oC.  
Aortic Ring Angiogenesis Assay 
Aortas extending from the aortic arch to the diaphragm were removed from five week 
old C57BL/6 wild type or MGP -/- mice. The aortic sections were washed in 1X PBS and 
dissected into small rings of equal sizes (~1mm) before implantation into fibrin gels. Fibrin 
gels were prepared by mixing 1.5 mg/ml fibrinogen with serum free EGM2 media (Lonza 
Inc.), and filtering through 0.22 μm sterile filters. The fibrin gel was formed by adding 0.06 
U/ml Thrombin to 0.5 ml fibrinogen solution in 24-well plates into which the aortic rings were 
immediately implanted. Fibrin gels were allowed to form at room temperature for 20 minutes 
before  being  overlaid  with  1  ml  EGM2  +  growth  factors  (Lonza  Inc.).  The  plates  were 
incubated  in  37
oC  in  a  5%  CO2  incubator.  Aortic  rings  were  observed  daily  for  signs  of 
angiogenic sprouting. Individual sprout lengths were measured after 10 days. 
MGP Morpholino Injection in Zebrafish 
The  MGP  specific  anti-sense  morpholino  (Genetools)  (5’  GAGACACACACATG 
ACTGCAGGAGC  3’)  was  designed  to  interfere  with  MGP  mRNA  translation  initiation. 
Morpholinos were dissolved in water and diluted 1:1 into 0.1% phenol red/water injecting 
solution.  12  ng  of  MGP  morpholino  was  injected  into  1  to  8  cells  Fli1-GFP/GATA1-RFP 
embryos  in  a  total  volume  of  0.9  nl  per  embryo.  Embryos  were  sedated  in  tricaine  and 
monitored for vascular phenotypes on a Nikon SMZ-1500 fluorescent dissecting microscope. 
Morpholinos directed against p53 were synthesized and used according to previously published 
work [169].      
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Immunohistochemistry 
Excised tissues were fixed in 4% paraformaldehyde for 1 hr and stored in 70% ethanol 
before paraffin embedding, sectioning, and staining with CD-31 antibody to visualize vascular 
structures in the Clarian Pathology Laboratory at Indiana University (Indianapolis, IN). To 
quantitate vascular density, CD-31 staining patterns were traced onto white paper with black 
ink and the resulting copy was scanned to obtain total vascular area using Image J software 
(NCBI). 
Immunobloting 
The N-terminally Flag-tagged human MGP (N-Flag-hMGP) plasmid was generously 
provided by Kristina Bostrom (UCLA, CA). Approximately, seventy five percent confluent 
293T cells in 10 cm plates were transfected with 10 µg of N-Flag-hMGP plasmid DNA using 
Trans-IT LT1 transfection reagents (Mirus Inc.) as per the manufacturer’s recommendations. 
After 24 hours, plates were washed with 1X PBS and cultured in serum free media (SFM) 
overnight.  Confirmation  of  MGP  expression  in  the  conditioned  media  was  performed  by 
precipitation with .1% DOC/TCA as described in our previous study [42] followed by western 
blot analysis using anti-flag M2-antibody.  
RT-PCR 
RT-PCR was performed to determine the expression of Delta Like-4 (DLL4), jagged-1, 
Hes-1, CD31, smooth muscle Actin, MGP, and GAPDH. Total RNA was isolated using Trizol 
reagents (Life technologies, Grand Island NY) as per the manufacturer’s instructions. cDNA 
was synthesized using the iScript cDNA Synthesis Kit (Bio Rad Inc.). Primer sequences, target 
genes, and PCR product sizes for each primer set are listed in Table 1. The PCR reactions were 
performed under the following conditions: 10 ng cDNA; 200 nM oligos; 320 µM dNTP; 1x      
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standard buffer; and 66 U/ml Taq Polymerase in a total reaction volume of 25 µl. Cycling 
parameters used were as follows: 1 cycle at 94
oC for 2 min; 30 cycles at 94
oC for 45 sec, 57
oC 
for 40 sec, and 72
oC for 60 sec; 1 cycle at 72
oC for 5 min; and hold at 4
oC.  
Transfections and Luciferase Assay 
Transient  transfection  of  human  microvascular  endothelial  cells  (HMEC)  was 
performed in triplicate in 24-well plates. HMEC cells were seeded into 24-well plates at 20,000 
cells/well 20-24 hrs prior to transfection. Individual wells were transfected with 200 ng of Hes-
1 luciferase plasmid and DNA25 ng of CMV β-galactosidase control plasmid using Trans-IT 
LT-1 (Mirus Inc.) reagent according to the manufacturer’s recommendations. Two days after 
transfection, the cells were lysed in 100 µl/well of Passive Lysis Buffer (Promega, Madison, 
WI), freeze-thawed, and centrifuged for 1 minute. Luminescence activities for luciferase and β-
galactosidase  were  measured  by  Glomax  Luminometer  using  Promega  luciferase  assay 
reagents according to the manufacturer’s recommendations.  
In-vivo Tumor Growth Studies 
Pancreatic  Adenocarcinoma  (PanO2)  cells  were  resuspended  in  sterile  phosphate 
buffered saline (PBS) and 1x10
6 cells per 100 μl were injected subcutaneously between the 
shoulder blades of approximately 10-week-old MGP -/+ and MGP +/+ C57BL/6 mice (three 
mice per condition; bred in-house). Mice were monitored on a daily basis and primary tumors 
were measured externally with calipers between days 9 and 17.  
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Supplementary Methods and Materials 
Invasion Assay 
For invasion assays, 100,000 endothelial cells suspended in control or MGP containing 
condition media were cultured (in triplicate) into the upper well of invasion chambers that were 
previously coated with matrigel. To the lower well of the invasion chamber, EGM-2 media was 
added and the cells were incubated overnight. Assays were fixed the following day with 95% 
ethanol and the invading cells were stained with 1X crystal violet. The density of invading 
cells was measured by densitometry of scanned membranes using ImajeJ (NCBI) software. 
Proliferation Assay  
For  proliferation  assay,  2000  endothelial  cells/well  were  cultured  in  EGM2  growth 
media supplemented with condition medium containing either control (empty vector) or human 
MGP (Flag-hMGP) plasmids. Cell proliferation in triplicate wells were examined daily over 
the next two days by measuring the fluorescent conversion of WST1 cell proliferation reagent 
essentially as described in our previous publications [83].  
Capillary Formation Assay 
For capillary formation assay, 200,000 cells/ml were treated with conditioned (hMGP 
containing) or control (empty vector) media and cultured into a matrigel containing culture 
plate. Cells were incubated overnight at 37C incubator.  
Wound Healing Assay 
Confluent plates of endothelial cells were scratched uniformly and were treated with 
conditioned (hMGP containing) or control (empty vector) media and cultured for few days. 
Wound healing was determined by relative migration of endothelial cells into the scratched 
region.      
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Results 
MGP Suppresses Endothelial-Sprouting In-vitro 
In  our  previous  study,  MGP  expression  was  significantly  increased  during 
angiogenesis, but the exact role of MGP in this context was not clear. Here, we used MGP 
deficient mice to study MGP function during angiogenesis. PCR based genotyping was used to 
identify MGP -/- mice and RT-PCR analysis was used to confirm the absence of MGP mRNA 
in MGP-/- animals (Figure S1).  Aortas were isolated from ~ 5 week old MGP +/+ or MGP -/- 
mice, sectioned, and implanted into fibrin gels.  As shown in fig 1A and B,  ~ 40% of the MGP 
-/- rings initiated sprouting on day 3 while MGP +/+ rings did not initiate sprouting until day 4. 
Furthermore, 100% of the aortic rings from MGP -/- mice had sprouted by day 5 whereas 
100%  of  the  MGP  +/+  rings  only  sprouted  by  day  7.  Finally,  after  ten  days  in  culture, 
angiogenic sprouts from MGP -/- rings were ~1.5 fold longer compared to angiogenic sprouts 
from MGP +/+ rings (Fig 1C).  To determine if MGP was directly responsible for suppressing 
aortic sprouting, we generated control or MGP containing conditioned media by transfection of 
293T cells (Figure S1) and applied these conditioned medias to MGP+/+ and MGP-/- aortic 
ring cultures.  As shown in figure 1, compared to control conditioned media, MGP containing 
conditioned  media  delayed  sprouting  initiation  and  decreased  final  sprout  length  in  both 
MGP+/+ and MGP-/- aortic cultures.   Collectively, these results showed that MGP normally 
acts to suppress angiogenic sprouting and suggested that either 1.) MGP is an endogenous 
inhibitor of angiogenesis, or 2.) that MGP does not inhibit angiogenesis per se, but rather is 
important for re-inforcing angiogenic resolution.  
MGP Suppresses Microvascular Density in Heart and Skeletal Muscles  
Based on the increased sprouting from MGP -/- rings, we predicted that MGP -/- mice      
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might have increased vascular densities compared to MGP +/+ mice. To investigate this, we 
isolated various tissues from MGP +/+ and MGP -/- mice and used immunohistochemistry 
with anti-CD31 antibodies to monitor vascular density. Compared to the MGP +/+ mice, MGP 
-/- mice had significantly increased CD-31 staining in heart (2.8 fold increase) and skeletal 
muscles (1.7 fold increase) (Fig 2A), suggesting that MGP inhibits formation of excessive 
microvasculature  in  these  tissues.    These  results  suggested  that  MGP  is  crucial  in  the 
maintenance of normal vascular densities in skeletal muscle and heart and further emphasized 
the importance of MGP in microvascular function.  
MGP Suppresses Tumor Angiogenesis 
In contrast to our results showing that MGP suppresses angiogenic sprouting, MGP was 
previously  shown  to  promote  tumor  angiogenesis  [145].   These  conflicting  observations 
suggested  that  MGP  may  have  differential  roles  in  normal  physiological  and  pathological 
angiogenesis  and  it  was  therefore  important  to  distinguish  between  these  possibilities.   To 
accomplish  this,  we  subcutaneously  injected  pancreatic  adenocarcinoma  (PanO2)  cells  into 
syngeneic MGP +/+ or MGP heterozygous (MGP +/-) mice and monitored tumor growth and 
vascular density in the resulting tumors. Performing this experiment in MGP +/- mice was 
necessary since MGP -/- mice typically die by five weeks of age, which prohibits long-term 
tumor studies whereas -/+ mice have normal life spans.  As shown in figure 3, tumors grew 
significantly faster (Fig 3A) and at dissection were approximately 2.5 fold larger in MGP +/- 
compared to tumors grown in MGP +/+ mice (Fig 3B, C).  Immunohistochemistry of tumor 
sections with anti-CD31 antibodies (Fig 3D, 3E) and RT-PCR analysis of CD31 mRNA (Fig 
3F, 3G) revealed that MGP +/- tumors contained approximately 1.5 fold more blood vessels 
compared to tumors grown in control mice.  Therefore, these results are consistent with our      
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previous  results  and  do  not  support  differential  roles  for  MGP  in  normal  vs.  pathological 
angiogenesis. 
MGP is Important for the Maintenance of Vascular Lumen Structures   
To  further  dissect  the  role  of  MGP  in  vascular  function,  we  examined  vascular 
development in zebrafish embryos injected with anti-MGP morpholinos. Multiple sequence 
alignment of MGP from seven different species including zebrafish indicated that MGP is 
highly conserved among species (Figure S2) and therefore suggested that MGP is likely to 
serve conserved functions in vascular development and function. RT-PCR was used to confirm 
expression of MGP mRNA in developing zebrafish. As shown in figure S2, MGP mRNA was 
expressed  as  early  as  10  hours  post  fertilization  (HPF)  and  continued  to  be  expressed 
throughout  the  observed  time  period.  This  was  consistent  with  previous  observations  that 
showed a similar pattern of MGP expression by immunohistochemistry in zebrafish [170]. 
Within  24  hours  after  morpholino  injections,  MGP  morphants  showed  a  progressive 
developmental defect characterized by an abnormal curvature of the back.  A slightly curved 
phenotype was observed on day 1 (Fig 4A) that became more prominent by day 3 (Fig 4B) and 
day 6 (Fig 4D).  MGP expression in zebrafish has been found in chondrocytes and is important 
for cartilage mineralization during bone formation [170]. In MGP -/- mice, MGP is important 
for  suppressing  pathological  calcification  of  ECM  [141].    Therefore  it  is  likely  that  the 
deformation  of  MGP  morphants  is  related  to  the  role  of  MGP  in  cartilage  and  bone 
development. Importantly however, despite the curved phenotype, normal body segmentation 
was observed (Fig 4A), which is requisite for vascular development [101].  Inspection of the 
vasculature  revealed  that  MGP  knockdown  slightly  delayed  the  angiogenic  sprouting  of 
intersegmental vessels (ISV) from aorta on day one (Fig 4A). However, by day 3 ISV vessels      
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in MGP morphants were similar to those in control fish suggesting MGP is dispensable for the 
initial establishment of vascular networks. This was consistent with our observations that MGP 
did not have an observable affect on activities operant during angiogenesis including invasion, 
proliferation, migration, and tube formation activity of endothelial cells (Figure S3). By day 3 
however, MGP-knockdown in the developing zebrafish caused a progressive loss of vascular 
luminal structures in the ISVs.  Day 3 MGP morphants had narrower ISV lumens compared to 
control fish (Fig 4C, arrows) and blood flow was partially blocked (Fig 4B). By day 6, luminal 
structures in MGP morphant aortas and ISVs were completely non-evident compared to the 
control fish (Fig D, E) and MGP morphants developed edema near the anterior side of the heart 
(Fig 4D, arrow).  Overall, these results suggested that MGP is not required for initial vascular 
development but is crucial for proper maintenance of normal vascular structure.  
MGP Decreases Notch Signaling in Cultured Endothelial Cells 
Notch activation by DLL4 and jagged-1 has opposing effects on endothelial sprouting 
during angiogenesis. Jagged-1 promotes endothelial sprouting and angiogenesis whereas DLL4 
suppresses sprouting and promotes vascular quiescence [115]. Interestingly, DLL4 knockdown 
in  zebrafish  [97],  DLL4  -/+  mice  [171],  and  Dll4  blockade  [112]  all  exhibit  excessive 
angiogenesis and loss of vascular lumen structures similar to our results with MGP -/- aortic 
rings and MGP morphants and  suggested a link between MGP and notch signaling. To test 
this, we utilized a notch responsive luciferase construct featuring the Hes-1 promoter upstream 
of  the  luciferase  gene  to  examine  notch  responsive  transcription  activity  in  Human 
Microvascular Endothelial cells (HMEC) cultured in control or MGP conditioned media. MGP 
containing conditioned media was prepared by transfection of MGP cDNA into 293T cells and 
expression was confirmed by western blot (Fig S1). Our luciferase data showed that HMECs      
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cultured in MGP conditioned media had decreased Hes-1 activity compared to the control 
HMECs  cultured  in  control  conditioned  media  (Fig  5A).  To  support  this  observation,  we 
performed RT-PCR analysis to determine if MGP controls expression of different components 
of the notch signaling pathway. To accomplish this, 10 day old aortic ring cultures from MGP 
+/+ and MGP -/- mice were collected by tryptic digestion of fibrin gels, removal of the original 
aortic ring, and extractions of RNA from the remaining outgrowths. RT-PCR analysis was 
performed to compare expression levels of smooth muscle actin (smActin), endothelial cell 
marker (CD-31), GAPDH, the Notch target gene Hes-1, and the notch ligands jagged-1 and 
DLL4.  RT-PCR  detected  expression  of  both  smooth  muscle  actin  (smActin)  and  CD-31, 
confirming that aortic outgrowths were co-cultures of smooth muscle and endothelial cells (Fig 
5B). More importantly however, expression of jagged-1 mRNA and Hes-1mRNA in MGP -/- 
outgrowths  was  elevated  compared  to  MGP  +/+  outgrowths  whereas  expression  of  DLL4 
mRNA remained unchanged (Fig 5B). Conversely, we also examined gene expression levels in 
HMEC cells treated with condition media collected from control or MGP transfected 293T 
cells (Fig 5C). Consistent with previous results, MGP significantly decreased expression of 
jagged-1 and Hes-1 mRNA but did not affect DLL4 mRNA expression. Collectively, this data 
provided a correlation between MGP function and notch signaling and suggested that MGP 
might inhibit angiogenic sprouting by suppressing jagged-1 expression. 
MGP Suppresses Aortic Sprouting Independently of Notch and VEGF Signaling 
Our results have shown that MGP suppressed angiogenic sprouting and Notch signaling 
in cultured aortic rings and isolated endothelial cells. Previously, MGP was shown to suppress 
BMP signaling [144, 147]. Interestingly, BMP and Notch signaling have been co-implicated in 
the development of vascular calcification [119], angiogenic sprouting [111] and BMP together      
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with Notch are reported to synergistically suppress VEGF expression [110, 167]. Based on 
these results, it was important to determine if enhanced aortic sprouting in the absence of MGP 
was a consequence of enhanced Notch, BMP, or VEGF signaling or a synergistic manipulation 
of these pathways.  To address this question, we monitored sprouting from control or MGP -/- 
aortic rings in the presence or absence of either the BMP antagonist Dorsomorphin, the γ-
secretase/Notch antagonist DAPT, or the VEGF inhibitor SU5416. As previously shown, MGP 
-/-  aortic  sections  demonstrated  significantly  enhanced  aortic  sprouting  compared  to  aortic 
rings from control mice (Figure 6A). Surprisingly, inhibition of Notch signaling with DAPT or 
inhibition of VEGF signaling with SU5416 had a minimal effect on aortic sprouting from 
either control or MGP knockout aortic rings indicating these signaling mechanisms play a 
minor role for angiogenic sprouting in this assay.  However, inhibition of BMP signaling with 
Dorsomorphin elicited a striking blockade on aortic sprouting from both control and MGP -/- 
aortic sections suggesting that BMP signaling is the predominant signaling system active under 
these  conditions.  Collectively,  these  results  show  that  BMP  is  critical  for  aortic  sprouting 
however, the complete suppression of sprouting in the presence of Dorsomorphin prevents a 
clear conclusion about the importance of MGP mediated BMP signaling in this assay. 
Discussion 
Arteriosclerosis,  atherosclerosis,  and  the  inappropriate  angiogenesis  within  tumors 
collectively account for some of the most common abnormalities of the vascular system. An 
important realization is that each of these diseases is strongly impacted by interactions between 
vascular cells and components of ECM (ECM) in the vascular microenvironment. In light of      
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this, growing interest has been shifted toward understanding the interplay between ECM and 
endothelial cell activity to dissect the pathophysiology of these vascular diseases.  
Matrix Gla protein is an ECM protein commonly found in vascular tissues [31, 141, 
165]  and  has  been  implicated  in  several  vascular  abnormalities  including  arteriosclerosis, 
atherosclerosis, arterial-venous malformations, and abnormal angiogenesis in tumors [31, 117, 
141, 145]. However, the functional role and mechanistic basis by which MGP impacts these 
abnormalities is unclear. In this study we used a combination of mice and zebrafish MGP 
knockout models coupled with cell and tissue culture approaches to refine our understanding of 
the role of MGP in vascular formation and function.    
In order to clarify the role of MGP in angiogenesis, we compared angiogenic sprouting 
from aortas dissected from wild type or MGP knockout mice. Angiogenesis encompasses both 
the activation phase wherein vascular networks are established by the proliferation, migration, 
and  invasion  of  endothelial  cells,  and  the  resolution  phase  wherein  vascular  networks  are 
stabilized and endothelial cell quiescence is established. Our results show that in the absence of 
MGP, aortic sprouts appeared significantly earlier and grew to greater lengths compared to 
control aortic rings (Figure 1). Similarly, Yao et al. showed that MGP suppresses pulmonary 
blood vessel branching [146]. This observation suggested that either MGP normally functions 
to reinforce the resolution phase of angiogenesis or that MGP actively suppresses the activation 
phase  of  angiogenesis.  Our  data  does  not  support  the  idea  that  MGP  actively  suppresses 
angiogenesis since we were unable to detect any impact of MGP on endothelial cell activities 
operant  during  angiogenesis  including  proliferation,  invasion,  migration,  and  capillary 
formation (Figure S3). Furthermore, our previous findings showed that MGP expression is 
increased during the later stages of endothelial network formation [83], which is consistent      
 
53 
with a role during resolution phase. Finally, ISV sprouting in zebrafish embryos was only 
minimally impacted by MGP knockdown and the initial establishment of functional vascular 
networks was normal in MGP morphants (Figure 4B). Therefore, we hypothesize that MGP is 
important for the establishment and maintenance of the endothelial quiescence program. In 
support of this hypothesis, CD31 staining of MGP knockout adult tissues revealed increased 
vascular  densities  in  heart  and  skeletal  muscle,  suggesting  a  failure  of  vascular  tissues  to 
achieve quiescence. In addition, tumors grown in MGP -/- mice contained more blood vessels 
than their control counterparts further illustrating the role of MGP in vascular development. 
Finally, the progressive loss of vascular lumens in MGP morphant zebrafish shows that MGP 
is  indispensable  for  the  maintenance  of  functional  vascular  lumen  structures,  an  important 
aspect  of  quiescent  vasculature.  Collectively,  these  data  suggest  that  MGP  does  not 
significantly impact angiogenesis activation, but rather is important during the resolution phase 
of angiogenesis.  
In  mice,  MGP  blocks  BMP-2/4/7  signaling  [117,  149].    In  the  absence  of  MGP, 
elevated  BMP  signaling  has  been  linked  to  vascular  defects  including  arteriosclerosis, 
atherosclerosis [31], and arterial-venous malformations [117].  However, in zebrafish embryos, 
it is not clear that MGP suppresses BMP since zebrafish MGP does not contain a BMP binding 
domain (Yao et al, 2008).  Moreover, the role of BMP signaling in zebrafish intersegmental 
vessel  formation  is  uncertain  since  the  BMP  responsive  BRE  promoter  is  not  active  in 
developing ISV vessels [172], and specific inhibition of BMP has been shown to have no affect 
on ISV formation [173]. However, BMP signaling has been implicated in angiogenic sprouting 
from the axial vein [8].  Taken together, it is not likely that the effect of MGP knockdown on 
zebrafish ISV luminal structures is strictly due to abnormal BMP signaling.  Interestingly,      
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BMP has been shown to function in synergy with Notch signaling [110, 111] thus potentially 
implicating Notch with our results.  
Activation  of  Notch  signaling  by  Jagged-1  or  DLL4  initiates  opposing  angiogenic 
activities.  Although opposing, a balance between Dll4 and Jagged-1 is required to establish 
and  maintain  functional  vasculature  [115].    DLL4  promotes  quiescent  stalk  cell  selection 
whereas jagged-1 opposes Dll4 by suppressing the stalk cell phenotype and instead inducing 
pro-angiogenic  tip  cell  selection  in  endothelial  cells.    Disruption  of  this  balance  by  Dll4 
knockdown in zebrafish allows the initial establishment of functional vasculature followed by 
excessive  angiogenic  sprouting  and  the  eventual  loss  of  vascular  lumen  structures  [97]. 
Similarly, blockade of notch ligand DLL4 has been implicated in the development of excessive 
but non-lumanized vessels in tumors [106, 112]. Similar to these results, we found that MGP 
morphants experienced a progressive loss of vascular lumen structures and that MGP-/- aortic 
rings exhibited excessive angiogenic sprouting compared to their control counterparts.  Based 
on these similarities, we hypothesized that MGP may function via the notch signaling pathway. 
In  support  of  this  hypothesis,  our  luciferase  data  revealed  that  MGP  suppressed  notch 
activation in endothelial cells. Moreover, our RT-PCR results from mouse aorta and HMEC 
cells showed that MGP suppressed Hes-1 and jagged-1 mRNA expression but did not alter 
DLL4 expression (Figure 5). Therefore, our findings suggested that MGP normally functions 
to maintain a balance between jagged-1 and DLL4 and that in the absence of MGP, excessive 
jagged-1 destabilizes stalk cell structures resulting in a failure to achieve a stable, quiescent 
vasculature.  Despite this data, BMP inhibition with Dorsomorphin but not Notch inhibition 
with DAPT completely blocked angiogenic outgrowths from both MGP+/+ and MGP-/- mouse 
aorta (Figure 6).  Therefore, while our in vitro gene expression data and zebrafish morpholino      
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data suggest that MGP functions through Notch in these systems, it is not yet clear if BMP, 
Notch, or an alternative signaling pathway is responsible for the enhanced sprouting observed 
in MGP -/- aortic ring cultures. 
MGP is not only associated with suppression of arteriosclerosis and atherosclerosis, but 
up-regulation of MGP has also been associated with poor prognosis in breast cancer [174], 
gastric cancer [175] and glioblastoma [145]. MGP appears to be significantly up regulated in 
these cancers and is under evaluation as a potential prognostic marker. In glioblastoma, MGP 
appears to promote tumor growth, angiogenesis [145], and migration of glioma cells [176]. In 
contrast, our findings in pancreatic adenocarcinoma (PanO2) showed that tumors grew more 
rapidly  and  were  more  densely  vascularized  in  MGP+/-  mice  compared  to  MGP+/+  mice 
(Figure 3), suggesting a pleiotropic role for MGP in various cancers. One possibility to explain 
these conflicting observations involves decreased MGP expression in early stage tumors to 
enable  angiogenesis,  and  increased  MGP  expression  in  larger  tumors  to  promote  vascular 
stabilization  and  increase  tumor  perfusion.    However,  it  is  evident  that  additional 
experimentation is required to more precisely define the role of MGP in tumor growth and 
angiogenesis.  
In summary, we have presented evidence suggesting that MGP promotes angiogenic 
resolution and vascular stabilization. Our findings provide a new avenue toward understanding 
the role of MGP in both large as well as small vessel dysfunctions. We believe these results 
will shed light on the pathogenesis of vascular diseases in which MGP is involved such as 
tumor angiogenesis, atherosclerosis, arteriosclerosis, and arterial-venous malformation.  
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Figure 1. Matrix Gla Protein (MGP) suppresses endothelial sprouting in mouse aortic rings.   
  A) Aortic rings from MGP +/+ and MGP -/- mice were implanted into fibrin gels, 
cultured for seven days, and photographed under low and high power magnification.  Shown 
are  representative  pictures  from  a  single  experiment  that  was  performed  four  times  in  its 
entirety.  Each experiment consisted of 6-8 aortic ring sections harvested from an individual 
control  or  MGP-/-  mouse.    B)  The  initiation  of  aortic  sprouting  was  monitored  daily  and 
graphed as a percentage of sprouting rings vs time.  Data presented are the average +/- SE of 
four  independent  experiments.    C)  Average  sprout  length  after  seven  days  in  culture  was 
measured  using  imageJ  software.    Data  represents  average  +/-  SE  of  four  independent 
experiments. In all experiments, ** indicates P< 0. 05, student’s t-test. 
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Figure 1D-F. D) MGP+/+ and MGP-/- aortic rings were cultures in the presence or absence of 
conditioned media collected 293T cells transfected with either empty vector (control) or MGP 
cDNA.  Shown are representative images from a single experiment that was performed three 
times in its entirety.  Each experiment consisted of 3-4 MGP+/+ or MGP-/- rings in control or 
MGP containing conditioned media.  E) Sprouting from MGP+/+ and MGP-/- aortic rings was 
monitored daily and the resulting data is depicted as in B.  F) Average sprout length was 
measured and the resulting data is presented as in C.  In all experiments, ** indicates P<0.05, 
student’s t-test.      
 
58 
 
Figure 2. MGP suppresses microvascular density in heart and skeletal muscles. 
A)  Vascular  density  in  heart  and  skeletal  muscle  was  monitored  by 
immunohistochemistry with anti-CD31 antibodies. Shown are representative images of a single 
experiment that was performed three times in its entirety. B) Quantification of CD-31 staining 
in heart tissue form MGP +/+ and MGP-/- mice was performed by imageJ analysis.  Data 
shown represents the average +/- SE of three independent experiments and is presented as the 
fold change compared to MGP+/+ tissue. C) CD31 staining in skeletal muscle (SKLM) was 
quantified and presented as in B. In both B and C, ** Indicates P<0.05, student’s-test.       
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Figure 3. MGP suppresses tumor growth and vascular density.  
A)  Tumor  growth  was  initiated  in  control  (MGP+/+)  or  heterozygous  (MGP+/-) 
C57BL/6 mice by subcutaneous injection (in triplicate) of 1x10
6 Pancreatic Adenocarcinoma 
(PanO2) cells. Tumor sizes were measured one week after injection and subsequently every 
other day.  Data shown depicts average tumor size +/- SE compared to tumors grown in control 
mice. B) Representative set of triplicate tumors from a single experiment that was performed 
three times in its entirety. C) Tumors mass was recorded and is presented as the average fold 
change  (+/-SE)  compared  to  MGP+/+  tumor  mass  (N=3).  In  all  experiments,  **  indicates 
P<0.05, Student’s t-test.        
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Figure  3D-E.  D)  Immunohistochemistry  with  anti-CD31  antibodies  was  used  to  monitor 
vascular  densities  in  tumors  from  MGP+/+  and  MGP+/-  mice.    E)  Anti-CD31  staining  in 
tumors was quantified by imageJ analysis and is presented as the average (+/- SE) compared to 
MGP+/+ tumors. In all experiments, ** indicates P<0.05, Student’s t-test. 
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Figure 3F-G. F) Total RNA was extracted from MGP+/+ and MGP+/- tumors and used for RT-
PCR analysis of CD31, MGP, and GAPDH mRNA expression.  Shown are representative 
images of a single experiment that was performed three times in its entirety.  G) CD31 RT-
PCR results were quantified by imageJ analysis and normalized by GAPDH signal.  Data 
shown depicts CD31 expression in MGP+/- compared to MGP+/+ control tumors and is the 
average (+/- SE) of three independent experiments.  In all experiments, ** indicates P<0.05, 
Student’s t-test. 
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Figure 4. MGP stabilizes vascular structure in zebrafish embryos.  
   A)  Bright  field  (BF)  and  endothelial  network  analysis  (GFP)  of  ~24  hour  post 
fertilization (hpf) embryos at low (middle panel) and high (right panel) magnification.  B) 
Analysis of bright field (BF), endothelial network (GFP), and flow dynamics (RFP) in 3 day 
post fertilization (dpf) embryos.  D) Analysis of bright field (BF), endothelial network (GFP), 
and flow dynamics (RFP) in 6 day post fertilization (dpf) embryos.  Arrow indicates site of 
edema accumulation in MGP morphant.        
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Figure 4C-E. C) High power imaging of endothelial networks in 3 dpf embryos injected with 
either vehicle or MGP morpholinos.  Arrows indicate sites of endothelial lumen restriction in 
MGP morphant. E) High power imaging of endothelial networks in 6 dpf embryos injected 
with either vehicle or MGP morpholinos. 
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Figure  5.  MGP  suppresses  notch  signaling  and  blocks  jagged-1  expression  in  sprouting 
endothelial cells.  
  A) Human microvascular endothelial cells (HMECs) were co-transfected with Hes-1 
luciferase + CMV- βgal constructs were cultured either with control condition media (Cont.) or 
MGP  containing  conditioned  media  (MGP).    Data  depict  the  average  (+/-SE)  of  four 
independent experiments and are presented as the fold change relative to HMEC cells cultured 
in control conditioned media.  In all panels, ** indicates P<0.05, student’s t-test.  
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Figure  5B.  MGP  suppresses  notch  signaling  and  blocks  jagged-1  expression  in  sprouting 
endothelial cells. Total RNA was collected from sprouted MGP+/+ or MGP-/- aortic rings and 
used to perform RT-PCR analysis of smooth muscle actin (smActin), endothelial cell marker 
(CD-31), GAPDH, Notch target Hes-1, and notch ligands jagged-1 and Delta like 4 (DLL4) 
genes.    Non-reverse  transcribed  samples  were  included  as  a  negative  control.    Shown  are 
representative images of a single experiment that was performed four times in its entirety.  
ImageJ analysis was used to compare Dll4, Jagged1, and Hes-1 mRNA in MGP+/+ and MGP-
/- aortic rings (right panel).  Data shown is the average (+/-SE) of four experiments presented 
as fold change compared to MGP+/+ samples.  In all panels, ** indicates P<0.05, student’s t-
test. 
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Figure  5C.  MGP  suppresses  notch  signaling  and  blocks  jagged-1  expression  in  sprouting 
endothelial cells. Total RNA was collected from HMECs cultured in conditioned media from 
293T cells transfected with empty vector (C), or MGP cDNA (M).   RT-PCR analysis was to 
monitor the relative mRNA expression levels of Hes-1, Jagged-1, D114, and GAPDH.  Non-
reverse transcribed samples were included as a negative control.  Shown are representative 
images from a single experiment that was performed three times in its entirety. ImageJ analysis 
was used to compare Dll4, Jagged1, and Hes-1 mRNA in the absence and presence of MGP 
(right panel).  Data shown is the average (+/-SE) of three experiments presented as fold change 
compared to MGP+/+ samples.  In all panels, ** indicates P<0.05, student’s t-test. 
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Figure 6. MGP suppresses aortic sprouting independently of Notch and VEGF Signaling.  
  A) Aortic rings were isolated from MGP+/+ or MGP-/- mice and embedded into fibrin 
gels containing vehicle (DMSO), gamma-secretase Notch inhibitor (DAPT), broad spectrum 
BMP  inhibitor  dorsomorphan  (Dorso),  or  VEGFR2  inhibitor  (SU5416).    Shown  are 
representative images were collected after 10 days in culture from a single experiment that was 
performed three times in it’s entirety.       
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Figure 6A (contd...). Aortic rings were isolated from MGP+/+ or MGP-/- mice and embedded 
into fibrin gels containing broad spectrum BMP inhibitor dorsomorphan (Dorso), or VEGFR2 
inhibitor (SU5416).  Shown are representative images were collected after 10 days in culture 
from a single experiment that was performed three times in it’s entirety.       
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Figure  6B.  Quantification  of  sprout  lengths.  Data  shown  is  the  average  (+/-SE)  of  three 
experiments  presented  as  fold  change  compared  to  MGP+/+  samples.    In  all  panels,  ** 
indicates P<0.05, student’s t-test.      
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Figure S1. Confirmations of mouse genotypes and MGP protein expression in 293T cells.  
  A) PCR based genotyping was used to identify MGP+/+, MGP+/-, and MGP-/- mice.  
PCR amplified 450 bp MGP product in MGP +/+ (WT) mice and 1 Kb mutant DNA product in 
the MGP -/- (KO) mice. B) RT-PCR showing lack or MGP mRNA expression in aortic ring 
cultures.  C) MGP containing conditioned media was made by transfecting 293T cells with 
empty  vector  or  N-terminally  flag  tagged  human  MGP  construct  (N-Flag-hMGP).  MGP 
overexpression  in  conditioned  media  was  confirmed  by  western  blot  analysis  of  condition 
media using anti-flag antibody.      
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Figure S2A. MGP is evolutionarily conserved across species.  
  MGP protein sequences from Human, Mouse, Orangutan, Zebra finch, Zebrafish, Rat, 
and  Pig  were  compared  using  the  Praline  sequence  alignment  tool 
(http://www.ibi.vu.nl/programs/pralinewww/). The degree of conservation for each amino acid 
is indicated by color according to the key and in the “conservation” line of the alignment where 
* indicates a fully conserved residue (i.e. 100% identity). Overall, the alignment showed 62% 
sequence identity over the entire length of the alignment.          
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Figure  S2B.  MGP  expression  was  detected  in  developing  transgenic  zebrafish  (fli-1-
GFP/GATA-1-RFP) embryos by RT-PCR analysis.  
  cDNAs were generated from embryos ranging from 2 to 48 hours and subjected to RT-
PCR analysis with MGP or GAPDH specific oligonucleotides. 
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Figure S3. MGP did not affect early angiogenic events including endothelial cell invasion, 
proliferation, capillary formation, and migration.  
  Endothelial cells treated with MGP conditioned (MGP) or control (Cont.) conditioned 
media were subjected to A) Invasion assay, B) Proliferation assay, C) Capillary formation 
assay, and D) Wound healing assay.      
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CHAPTER IV 
LUMICAN EXIHIBITS ANTI-ANGIOGENIC ACTIVITY IN A CONTEXT SPECIFIC 
MANNER 
 
Abstract 
Lumican belongs to small leucine rich proteoglycan (SLRP) family of ECM proteins. 
We have previously shown the anti-angiogenic effect of Lumican in various cancer models. 
However, these studies were primarily based on exogenously overexpressed Lumican in cancer 
cell lines and the results were insufficient to separate the effect of Lumican from the host. 
Here,  we  ask  whether  the  endogenous  Lumican  also  has  anti-angiogenic  properties  and  if 
Lumican’s  activity  is  similar  between  physiological  versus  pathological  angiogenesis.  Our 
PanO2  tumor  study  in  knockout  mice  shows  that  Lumican  is  an  endogenous  inhibitor  of 
angiogenesis in the tumor and restricts the tumor growth. However, Lumican shows a null 
effect  in  physiological  angiogenesis  since  we  did  not  find  any  difference  in  angiogenic 
response between Lumican WT and KO mouse measured by matrigel plug assay and aortic 
ring assay.  Interestingly,  however,  Lumican did  not  have  an  anti-angiogenic  effect  in  4T1 
breast cancer but suppressed 4T1 metastasis to lungs. Collectively, we show that Lumican as 
an anti-tumorigenic agent but its anti-angiogenic effect is context dependent.         
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Introduction 
The cellular microenvironment provides critical input as cells attempt to achieve and 
maintain  cellular  homeostasis.    In  particular,  extracellular  matrix  (ECM)  proteins  in  the 
microenvironment govern a variety of processes such as proliferation, migration, apoptosis, 
and response to cellular signaling stimuli.  While ECM provides critical input to cells and 
tissues,  cells  also  remodel  their  local  microenvironment  to  reinforce  cellular  activities  and 
programs.    Because  of  this  interplay  between  cells  and  ECM,  altered  cellular 
microenvironments can have profound impacts on various disease states.  In particular, the 
development and growth of cancers involves pathological remodeling of ECM into a reactive 
tumor  stroma  that  supports  cellular  programs  of  malignancy  and  drives  the  growth, 
neovascularization, invasion, and metastasis of tumors. 
While  reactive  tumor  stroma  generally  promotes  tumor  aggressiveness,  not  all 
components of the tumor stroma work in favor of the tumor.  Instead, there have also been 
identified several ECM molecules that possess distinct anti-tumor, anti-angiogenic, and anti-
metastatic activities.  Identification and characterization of these anti-cancer ECM proteins 
represents an important therapeutic avenue towards suppressing cancer in humans. 
Lumican  is  a  member  of  small  leucine  rich  proteoglycan  (SLRPs)  family  of 
extracellular matrix (ECM) proteins. The structural role of Lumican is attributed toward its 
ability to promote fibrillogenesis and stabilization of collagen fibers [153, 177].  Lumican is 
also a matricellular protein that interacts with the VEGF, FGF and Fas [42, 83] signaling 
mechanisms.  However, in recent years, growing evidence has implicated Lumican in cancer 
and angiogenesis.  To this end, differential expression of Lumican has been detected in cancers 
of  the  breast,  colon,  cervix,  and  pancreas  [157,  159,  161,  178-182].    However,  a  clear      
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correlation  between  differential  Lumican  expression  and  cancer  malignancy  has  yet  to  be 
identified.    This  is  surprisingly  given  that  in  experimental  models  of  tumor  angiogenesis, 
Lumican has consistently demonstrated significant anti-angiogenic activity [42, 83, 162, 183]. 
The  results  of  this  study  confirm  the  anti-angiogenic  activity  of  Lumican,  but  also 
demonstrate that Lumican is not anti-angiogenic under all circumstances.  Rather, we find that 
Lumican suppresses angiogenesis in some but not all cancer models and that Lumican does not 
suppress angiogenesis in non-pathological settings including healing wounds, cultures of aortic 
rings, and matrigel plugs. 
Materials and Methods 
Wound Healing Model 
Control  and  Lumican  knockout  Male  C57BL/6  mice  were  anaesthetized  by 
intraperitoneal injection of ketamine hydrochloride (2 mg/g body weight) and xylazine (0.4 
mg/g body weight). Shaved skin was sterilized using an alcohol swab and a biopsy punch was 
applied  to  create  a  circular  full  thickness  skin  wound  about  6  mm  in  diameter  below  the 
shoulder blades.  Mice were sacrificed and tissues were collected 3, 7, 14, and 21 days after 
wounding. 
Mouse Breeding and Genotyping 
Lumican -/- mice in C57BL/6 background were generously provided by. Heterozygous 
(Lum -/+) male and female mice were crossed produce homozygous knockout (Lum -/-) mice. 
PCR based genotyping was performed on DNA isolated from ear tissue using DirectPCR Lysis 
Reagent (Viagen Biotech, Inc, LA, CA) to identify the mouse genotype. PCR was performed 
using specific primers targeting wild type vs. mutant Lumican alleles. The wild type primer set 
targeted 190 bp wild type Lumican allele whereas the mutant primer pairs targeted a 390 bp      
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mutant allele. Wild type and mutant PCR reactions were performed in a single reaction using 
following conditions: 1 µl template DNA (extracted from ear sample), 100 nM primers, 1X 
standard buffer, 320 µM dNTPs, and 66 U/ml Taq Polymerase (New England Bio Labs Inc.), 
and total volume 25 µl. Thermocycle conditions used for each reactions are as follows: 94°C 
for 2 min (1X); [94°C for 45 sec; 64°C for 30 sec; 72°C for 30 sec] (35X); 72°C for 5 min 
(1X); and 4°C.  
Immunohistochemistry 
Tumors were isolated, sectioned, and fixed in 4% paraformaldehyde for 1 hour and 
placed  in  70%  ethanol  before  paraffin  embedding,  sectioning,  and  staining  with  CD-31 
antibody to analyze microvascular densities in tumors in the Clarian Pathology Laboratory at 
Indiana University (Indianapolis, IN). Quantification of vascular density was performed by 
tracing CD-31 patterns onto white paper with black ink and scanning the resulting copy to 
obtain total vascular area using Image J software (NCBI).  
In-vivo Tumor Growth and Metastasis Studies  
Freshly cultured Pancreatic Adenocarcinoma (PanO2) cells were resuspended in sterile 
1X PBS and 1x10
6 cells per 100 µl were injected subcutaneously between the shoulder blades 
of approximately 10-week-old Lumican WT, HET, and KO C57BL/6 mice (three mice per 
condition).  For  4T1,  4000  cells  per  100  µl  were  injected  directly  into  breast  fat-pads  of 
syngeneic BalbC mice. Tumors in mice were monitored on a daily basis and primary tumors 
were measured externally using calipers between days 7-15 in an interval of 2 days. Metastasis 
to lungs was monitored by dissecting both lungs from tumor bearing mice, mincing the tissue 
with a razor, and chemically digesting the minced lung tissue for 2 hours with collagenase      
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solution.  Large undigested pieces of lung were allowed to settle, then 10 X 10
6 cells were 
plated into 10 cm dishes in the presence of 6-thioguanine to kill normal cells and select for 
resistant  4T1  cells  present  in  lung.    After  approximately  10  days  in  culture,  colonies  of 
metastatic cells were stained with crystal violet and overall staining density was determined 
with image-J software. 
In-vitro Angiogenic Outgrowth Assay (Aortic Ring Assay) 
Aortas (~1 cm in length) were removed from 5 week old C57Bl/6 wild type or Lum -/+ 
or Lum -/- mice. The aortic sections were washed in 1X PBS and cut into small rings of equal 
sizes and implanted into fibrin gels. Fibrin gels were prepared by mixing 1.5 mg/ml fibrinogen 
with serum free EGM2 media (Lonza Inc.), and filtering through 0.22 µm sterile filters. The 
fibrin gel was formed by adding 0.06 U/ml Thrombin to 0.5 ml fibrinogen solution in 24-well 
plates into which the aortic rings was immediately implanted. After fibrin gels are formed at 
room temperature for 20 minutes, 1 ml EGM2 complete media (Lonza Inc.) was added from 
the top. The plates were incubated in 37°C in a 5% CO2 incubator. Aortic rings were observed 
daily for signs of angiogenic sprouting and recorded. Individual sprout lengths were measured 
after 10 days of culture.  
Matrigel Plug Assay 
Matrigel implantation was performed on 6-week-old C57BL/6 WT, HET, or KO mice. 
Briefly  mice  were  injected  subcutaneously  in  the  ventral  groin  area  with  Matrigel  (700 
µl/injection; BD Biosciences, Bedford, MA) supplemented with bovine bFGF (300 ng/mL; 
R&D Systems, Minneapolis, MN). Seven days postimplantation, the mice were sacrificed and      
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the  plugs  were  harvested.  Three  mice  were  used  per  experimental  condition  and  the 
experiments were repeated thrice in its entirety.  
Results 
Lumican Is an Endogenous Inhibitor of Angiogenesis   
Previously,  Lumican  was  shown  to  decrease  tumor  angiogenesis  in  pancreatic 
adenocarcinoma (PanO2) cells, MCA102 fibrosarcoma cells, and B16F10 melanoma cells [42, 
184].  However, these studies relied on ectopic expression from implanted tumors to drive 
Lumican expression and therefore fail to account for host expression of Lumican.  Therefore, 
we  compared  the  growth  and  angiogenesis  of  tumors  formed  by  injection  of  pancreatic 
adenocarcinoma  (PanO2)  cells  in  wild-type  (WT),  heterozygous  (HET),  and  Lumican 
knockout (KO) mice.  Importantly, the PanO2 cell line was previously used to illustrate the 
anti-angiogenic activity of overexpressed Lumican in vivo [42] and therefore made an ideal cell 
line with which to examine host Lumican contributions to tumor growth and angiogenesis.  
Wild-type C57BL6 mice, or HET and KO littermates were identified by PCR as demonstrated 
in  Figure  1A.    PanO2  tumor  growth  in  Lumican  KO  mice  was  significantly  accelerated 
compared to tumor growth in WT mice (Fig. 1B).  Tumor growth in Lumican HET mice 
strongly tended toward accelerated growth although this increase in growth rate failed to reach 
statistical  significance.    At  dissection,  tumors  recovered  from  KO  and  HET  mice  were 
approximately 4.4 and 2.2 fold larger respectively than tumors recovered from WT mice (Fig. 
1C).  To determine if host expressed Lumican also suppressed PanO2 tumor angiogenesis, 
tumors were dissected from WT, HET, and KO mice and processed for immunohistochemistry 
with anti-CD31 antibodies to detect vascular elements.  As shown in figure 2, both Lumican 
KO and HET tumors exhibited a striking increase in vascular density.  Interestingly, vessels in      
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Lumican  KO  and  HET  tumors  tended  to  be  of  larger  caliber  than  their  WT  counterparts.  
Densitometry with imageJ software revealed 4.0 and 2.7 fold more CD31 staining in Lumican 
KO  and  HET  tumors  respectively.    Collectively,  these  results  illustrated  that  host  derived 
Lumican  suppresses  tumor  growth  and  angiogenesis  in  a  similar  fashion  to  ectopically 
expressed Lumican and therefore indicated that Lumican is an endogenous inhibitor of PanO2 
tumor angiogenesis. 
Lumican Suppresses Breast Cancer Growth and Metastasis, but Not Angiogenesis 
The  fact  that  host  derived  Lumican  suppressed  angiogenesis  in  PanO2  tumors 
confirmed  our  previous  results  showing  that  Lumican  overexpression  suppresses  tumor 
angiogenesis  [42]  and  indicated  that  Lumican  is  an  endogenous  inhibitor  of  angiogenesis.  
However, the role of Lumican in many other cancers remains undefined.  Therefore, to further 
investigate the potential anti-cancer role for Lumican, we studied the function of Lumican in 
breast cancer, a pathology wherein Lumican has been alternatively correlated with increased 
and decreased malignancy but has not been directly assayed [156, 179].  To clarify the role of 
Lumican  in  breast  cancer,  we  created  Lumican  overexpressing  breast  cancer  cell  lines  by 
transducing NMuMg normal murine mammary gland, and 4T1 breast cancer cell lines with 
retroviral  particles  encoding  either  Lumican  or  empty  vector  control  sequences.  
Overexpression  of  Lumican  in  the  resulting  cell  lines  was  confirmed  by  TCA/DOC 
precipitation of conditioned media followed by western blotting with either anti-Myc 9E10 
(NMuMg)  or  anti-FLAG  M2  (4T1)  antibodies  to  detect  C-terminally  tagged  Lumican 
transgene expression.  As shown in figure 3A and B, transgene expression of Lumican protein 
was evident in overexpressing cell lines but not in empty vector control cells.  To determine of 
Lumican  had  a  direct  affect  on  breast  cancer  cells,  we  compared  proliferation  rates  and      
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invasive activity in control and Lumican overexpressing cells.  As shown in figure 3C and D, 
Lumican did not significantly affect cell proliferation in either NMuMg or 4T1 cell lines but 
did significantly decrease cell invasion through Matrigel coated Boyden chambers in both cell 
lines (Fig 3E, F). 
Having  shown  that  Lumican  suppresses  breast  cancer  cell  invasion  in  vitro,  it  was 
important  to  determine  if  Lumican  suppresses  tumor  growth,  angiogenesis,  and 
invasion/metastasis  in  vivo.    To  accomplish  this,  control  and  4T1-Lumican  cells  were 
orthotopically injected into the fatpad of syngenic BALB/c mice.  After seven days, tumors 
were measurable and tumor volume was recorded every other day for fourteen days.  As shown 
in figure 4A, Lumican overexpressing 4T1 cells formed tumors significantly slower than their 
control  counterparts.    Moreover,  Lumican  expression  decreased  the  final  tumor  mass  by 
approximately 70% compared to control tumors (Fig 4B).  To determine if reduced tumor mass 
was associated with reduced tumor angiogenesis, sections of control and 4T1-Lumican tumors 
were sectioned and stained with anti-CD31 antibodies.  Surprisingly, we were unable to detect 
any difference in the vascular density between control and 4T1-Lumican tumors (Fig D, E).  
Given our in vitro data showing that Lumican suppressed 4T1 and NMuMg invasion, it was 
important to determine if Lumican suppressed 4T1 invasion/metastasis in vivo.  To accomplish 
this, lungs were collected from control or Lumican overexpressing tumors and rendered to 
single cell suspensions by digestion with Collagenase solution.  Equal numbers of cells were 
subsequently cultured on tissue culture dishes in the presence of 6-thioguanine to select for 
4T1 cells/colonies.  As shown in figure 5, lungs from Lumican overexpressing cells generated 
significantly fewer 4T1 colonies compared to lungs from control animals.      
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Collectively,  these  results  showed  that  Lumican  blocks  breast  cancer  growth  and 
metastasis to lung independently of angiogenesis suppression.  Interestingly, this was the first 
example wherein Lumican failed to suppress angiogenesis and suggested that Lumican may 
not be a universal inhibitor of angiogenesis but rather may inhibit angiogenesis only under 
restricted circumstances.   
Endogenously Expressed Lumican Does Not Suppress Non-Pathogenic Angiogenesis 
Based  on  our  results  showing  that  Lumican  did  not  suppress  angiogenesis  in  4T1 
tumors, we were interested to determine if there are other circumstances where Lumican does 
not  suppress  angiogenesis.    In  particular,  new  blood  vessels  are  a  crucial  component  of 
granulation  tissue  where  they  help  drive  tissue  healing.    Therefore  we  compared  vascular 
density in healing wounds from control and Lumican KO mice.  Cutaneous wounds were made 
by punch biopsy and the resulting healing wounds were collected 3, 7, 14, and 21 days after 
initial  wounding.    Wound  samples  were  stained  with  anti-CD31  antibodies  to  visualize 
neovascularization in the healing wounds.  As shown in figure 6, similar densities of CD31 
staining were detected at all time points in WT and KO mice suggesting that Lumican did not 
significantly affect angiogenesis in healing tissue.  In addition, we also compared angiogenic 
sprouting from WT, HET, and KO aortic rings.  Aortas were isolated from WT, HET, and KO 
mice, embedded into fibrin gels, and monitored over a ten day period for signs of angiogenic 
sprouting.  As shown in figure 7A, the initiation of angiogenic sprouting was indistinguishable 
between WT, HET, and KO rings.  In addition, the final length of aortic outgrowths was not 
significantly  longer  in  HET  and  KO  cultures  compared  to  WT  outgrowths  (Fig  7B).  
Importantly, RT-PCR confirmed the presence of Lumican in WT aortic outgrowth indicating 
that the failure to observe a decrease in angiogenic sprouting was not due to the absence of      
 
84 
Lumican expression (Fig. 7C).  Finally, we also examined the affect of Lumican deletion on 
Matrigel plug angiogenesis.  Our previous results demonstrated that recombinantly produced 
and purified Lumican suppressed angiogenesis in matrigel plugs [83].  Therefore, this system 
provided a unique opportunity to directly compare exogenous versus endogenous Lumican 
angiostatic activity.  Solutions of matrigel containing 300 µg/ml of bFGF were subcutaneously 
injected into either WT, HET, or Lumican knockout mice and ten days later were dissected and 
compared for evidence of vascularization.  As shown in figure 7E matrigel plugs dissected 
from WT, HET, and KO mice all contained similar amounts of blood suggesting angiogenesis 
was not altered in the absence of Lumican.  Importantly RT-PCR detected Lumican mRNA in 
control matrigel plugs indicating that Lumican was present in the matrigel plugs (Fig. 7F).  
Collectively, the failure of Lumican deletion to affect angiogenesis in healing wounds, aortic 
ring assays, or matrigel plugs strongly suggested that endogenously expressed Lumican is anti-
angiogenic only under certain circumstances. 
Discussion 
We and others have begun to unravel the function of Lumican in experimental models 
of cancer and angiogenesis however there remains significant questions regarding Lumican 
function in these processes.  One persisting question has to do with the fact that although 
Lumican has until now been shown to consistently suppresses angiogenesis [42, 83, 183], 
Lumican  is  nonetheless  commonly  over  expressed  in  cancers  but  does  not  consistently 
correlate with decreased malignancy as would be predicted for an angiogenesis inhibitor.  Our 
current results help clarify this quandary by showing that Lumican’s anti-angiogenic activity 
manifests only under restricted circumstances.  In combination with our previous results [42] 
we  have  found  that  both  overexpressed  and  endogenously  expressed  Lumican  suppressed      
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angiogenesis in PanO2 tumors while overexpressed Lumican failed to suppress angiogenesis in 
4T1 breast cancer tumors.  Therefore, we believe that the failure of Lumican to consistently 
correlate with decreased cancer malignancy is due to the differential ability of Lumican to 
suppress  angiogenesis  in  various  tumor  types.    The  mechanistic  basis  for  this  remains 
unexplored, but several hypotheses seem probable.  For example, heterogeneous endothelium 
within different tissues or tumor types [185] may have differential sensitivity to Lumican.  
However, our data does not support this since recombinant Lumican, but not endogenously 
expressed Lumican suppressed angiogenesis in matrigel plugs ([83], and Fig. 7).  Based on this 
observation, an alternative hypothesis is that non-glycosylated Lumican core protein such as 
recombinantly  produced  protein  blocks  angiogenesis  while  endogenously  expressed  and 
glycosylated Lumican is unable to suppress angiogenesis.  If correct, it will be critical in future 
studies to compare Lumican glycosylation in various tumor cell types.   Future studies will be 
directed at testing this hypothesis. 
Despite  the  fact  that  Lumican  did  not  suppress  4T1  tumor  angiogenesis,  Lumican 
overexpression did potently suppress 4T1 tumor growth and metastasis.  This result indicates 
that in addition to Lumican’s anti-angiogenic activity, this matricellular molecule also directly 
impacts tumor cell physiology.  This finding is consistent with our findings that Lumican 
suppresses 4T1 invasion and recent findings showing that Lumican suppresses melanoma cell 
migration by binding to α2β1 integrins and suppressing MMP14 activity [162].  Thus, the 
direct affect on tumor cell invasion and migration coupled with the anti-angiogenic activity of 
Lumican indicates that Lumican is a multi-functional matricellular protein that like many other 
matricellular molecules exhibits contextual specific activities.      
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Finally,  we  also  investigated  the  anti-angiogenic  activity  of  Lumican  in  non-tumor 
models  of  angiogenesis  and  were  unable  to  detect  a  significant  anti-angiogenic  activity  in 
wound healing assays, aortic ring assays, or matrigel plug implantations.  These results are also 
consistent  with  our  previous  results  showing  that  wound  healing  is  delayed  in  Lumican 
knockout  mice,  not  accelerated  as  would  be  expected  if  Lumican  is  anti-angiogenic  in 
granulation tissue [186].  Moreover, as is the case for tumors, these results seem to indicate that 
Lumican is only anti-angiogenic under restricted circumstances.  More provocatively, these 
results  also  suggest  that  the  anti-angiogenic  activity  of  Lumican  functions  only  within  a 
restricted subset of tumor microenvironments therefore raising the possibility that Lumican 
may represent an attractive therapeutic avenue to specifically inhibit angiogenesis in some 
tumors while sparing angiogenesis in other tissues such as healing wounds. 
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Figure 1. Lumican is an endogenous inhibitor of tumor growth. 
A) PCR based genotyping. PCR amplified 190 bp Lumican product in wild type (WT) 
mice and 390 bp mutant DNA product in Lumican knockout (KO) mouse. PCR amplified both 
190 bp Lumican product and 390 bp mutant DNA product in heterozygous (HET) mouse. 
Freshly  cultured  1  x  10
6  Pancreatic  Adenocarcinoma  (PanO2)  cells  were  injected 
subcutaneously into WT, HET, and KO mice and the tumors were allowed to grow in mice for 
15 days. Tumor sizes were measured externally using calipers after a week post injection at an 
interval  of  2  days.  B)  Graph  represents  a  tumor  growth  curve.  C)  Representative  tumors 
isolated from mice after 15
th day. D) Bar graph representing final tumor weights from WT, 
HET, and KO mice. Each data point represents Mean ±SD. ** indicate P<0.05, Student’s t-test, 
N = 3.       
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Figure 2. Endogenous Lumican has anti-angiogenic activity in Pancreatic Adenocarcinoma. 
PanO2 tumor isolates from mice were sectioned, fixed, and stained with anti-CD-31 
antibody to detect microvascular density in tumors. Shown are representative immunostaining 
results from a single experiment that was performed three times in its entirety.  CD-31 staining 
was quantified by densitometry with image-J software and is depicted as the fold increase 
compared  to  control  mice.  Each  data  point  represents  the  mean  ±SE  of  three  independent 
experiments. ** indicates P<0.05, Student T-test.        
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Figure 3 A-B). Confirmation of Lumican overexpression in 4T1 and NMuMG breast cancer 
cells.  
  4T1  and  NMuMg  breast  cancer  cells  were  transduced  with  either  empty  vector  or 
Lumican expressing retroviral vectors.  Overexpression of Lumican was confirmed by western 
blot analysis of TCA/DOC precipitated conditioned media.        
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Figure 3 C-D). Effect of Lumican on the proliferation of breast cancer cells.   
WST1 reagent was used to compare proliferation rates of empty vector control and 
Lumican overexpressing 4T1 and NMuMg cells.  Proliferation was measured daily for three 
days.  Data is depicted as average fold increase (+/- SE) of four independent experiments 
compared to empty vector control on day 1. 
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Figure 3E-F). Effect of Lumican on breast cancer cell invasion.   
Empty  vector  control  and  Lumican  overexpressing  4T1  or  NMuMg  cell  lines  were 
cultured  on  Matrigel  coated  Boyden  chambers  and  induced  to  invade  towards  a  2%  FBS 
gradient  for  48  hours.    Invading  cells  were  stained  with  crystal  violet  and  quantified  by 
densitometry.    Data  presented  is  the  average  fold  decrease  +/-  SE  of  four  independent 
experiments.  ** Indicates p<0.05, student’s t-test.       
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Figure 4. Lumican suppresses but not angiogenesis in 4T1 breast cancers. 
A) Equal numbers of empty vector control and Lumican overexpressing 4T1 breast 
cancer  cells  were  orthotopically  injected  in  triplicate  into  the  fat-pad  of  syngenic  mice.  
Tumors were evident after 7 days and tumor volume was measured every other day for 14 
days.    Tumor  volume  is  depicted  as  average  fold  increase  (+/-  SE)  of  three  independent 
experiments  compared  to  control  tumors  on  day  7.    B)  Representative  pictures  of  tumors 
dissected from a single experiment.  C) Final mass of dissected tumors was compared and is 
depicted as the average decrease (+/- SE) of three independent experiments compared to final 
control tumor mass.  ** Indicates p<0.05, student’s t-test.  D) Dissected tumors were sectioned 
and vascular density was monitored by immunohistochemistry with anti-CD31 antibodies.  E) 
Densitometry by image-J software was used to quantify CD31 staining in tumor sections.      
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Figure 5. Lumican suppresses 4T1 breast cancer metastasis to lungs. 
A) Images showing metastatic colonies of 4T1 breast cancer cells in lungs from mice 
injected  with  control  or  Lumican  overexpressing  (Lumican)  4T1  breast  cancer  cells.  B) 
Represents  a  quantification  of  metastatic  colonies  in  lungs  from  mice  injected  with  either 
control or Lumican overexpressing (Lumican) 4T1 cancer cells. Each data point represents 
Mean±SD. ** indicate P<0.05, Student’s t-test, N = 3.  
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Figure 6. Endogenous Lumican does not suppress angiogenesis in healing wounds.  
 Skin punches from wild-type (WT) and Lumican knockout (KO) mice were removed 
to produce wounds.  Healing wounds were collected from mice 3, 7, 14, or 21 days after 
wounding  and  vascular  density  was  compared  by  immunohistochemistry  with  anti-CD31 
antibodies. 
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Figure  7.  Endogenous  Lumican  does  not  suppress  aortic  sprouting  or  vascularization  of 
Matrigel plugs.   
A) Aortas were isolated from wild-type (WT), heterozygous Lumican knockout (Het), 
or homozygous Lumican knockout (KO) mice and sectioned then implanted into fibrin gels.  
Aortic cultures were inspected daily for angiogenic sprouting.  The time required to initiate 
angiogenic  sprouting  is  depicted  as  the  percent  number  of  sprouting  rings  over  a  10  day 
window until 100% of rings had sprouted.  Data presented is the average of four individual 
experiments each consisting of at least 5 aortic rings for each genotype.  B) The final length of 
angiogenic sprouts was measured (pixel length) and average length compared to WT rings is 
depicted. C) Lumican mRNA expression was confirmed in WT culture of aortic rings.  A 
negative reverse transcription (-RT) control was used to control for specific Lumican mRNA 
amplification.   
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Figure 7D-E. D) Representative images of WT, Het, and KO aortic ring cultures after 9 days in 
culture.  E) Solutions of Matrigel containing 300ng/ml of bFGF were injected subcutaneously 
into  WT,  Het,  and  Lumican  KO  mice.    After  10  days,  the  resulting  Matrigel  plugs  were 
dissected and blood content was compared as a sign of vascularization.  RT-PCR was used as 
in C to confirm expression of Lumican in control Matrigel plugs. 
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